

ASSOCIATE EDITOR: ERIC BARKER

# Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders

Gregory Hook, Thomas Reinheckel, Junjun Ni, Zhou Wu, Mark Kindy, Christoph Peters, and Vivian Hook

*American Life Science Pharmaceuticals, La Jolla, California (G.H.); Institute of Molecular Medicine and Cell Research, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany (T.R.); German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany (T.R.); German Cancer Research Center (DKFZ), Heidelberg, Germany (T.R.); Center for Biological Signaling Studies BIOS, Albert Ludwigs University, Freiburg, Germany (T.R.); Key Laboratory of Molecular Medicine and Biotherapy, Department of Biology, School of Life Science, Beijing Institute of Technology, Beijing, China (J.N.); Department of Aging Science and Pharmacology, OBT Research Center, Faculty of Dental Science, Kyushu University, Fukuoka, Japan (Z.W.); Taneja College of Pharmacy, Department of Pharmaceutical Sciences, University of South Florida, Tampa, Florida (M.K.); James A Haley VAMC, Research Service, Tampa, Florida (M.K.); Institute of Molecular Medicine and Cell Research, Faculty of Biology, Albert Ludwigs University, Freiburg, Germany (C.P.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, CA (V.H.); and Department of Neuroscience and Department of Pharmacology, School of Medicine, University of California, La Jolla, CA (V.H.)*

Abstract	611
Significance Statement	612
I. Introduction	612
II. Cathepsin B is Elevated in Human Neurologic Disorders	612
III. Cathepsin B Genetic Mutations Increase Cathepsin B and Cause Human Diseases	613
IV. Cathepsin B Is Elevated in Animal Models of Neurologic Diseases	615
V. Cathepsin B Neurobiology	615
A. Cathepsin B Is a Cysteine Protease	615
1. Cathepsin B Protease Activity	615
2. Cathepsin B Maturation	616
B. Cathepsin B in Brain and Subcellular Organelles	616
C. Cathepsin B Lysosomal Leakage Causes Inflammation and Cell Death in Neurologic Disorders	618
D. Endogenous Inhibitors of Cathepsin B	619
VI. Gene Knockout Mice for Target Validation and Drug Discovery	619
A. Mouse Gene Knockout Studies to Understand Mechanisms of Human Diseases	619
1. Gene Knockout Approach	619
2. Limitations and Controls for Gene Knockout Studies	619
B. Gene Knockout Mice in Drug Discovery	620
1. Drug Targets Assessed by Gene Knockout	620
2. On- and Off-Target Drug Effects Assessed in Gene Knockout Mice	621
VII. Cathepsin B Knockout Mice Are Generally Indistinguishable from Wild-Type Healthy Animals	621
VIII. Cathepsin B Knockout Improves Behavioral Deficits in Neurologic Disease Animal Models	622
A. Cathepsin B in Neuromotor Dysfunction, Brain Tissue Loss, and Hippocampal Cell Death in Traumatic Brain Injury	622

**Address correspondence to:** Dr. Vivian Hook, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive MC0657, La Jolla, CA 92093-0657. E-mail: vhook@ucsd.edu

This work was supported by National Institutes of Health National Institute of Neurological Disease and Stroke [Grant R01-NS109075] (to V.H.) and [Grant R41-NS110147] (to G.H.); the Deutsche Forschungsgemeinschaft, under Germany's Excellence Strategy [BIOS-EXC-294] (to T.R.); the Collaborative Research Centre 850 [project B7] (to T.R.); GRK 2606 [Project ID 423813989] (to T.R.); the German Cancer Consortium DKTK [projects L627 and FR01-371] (to T.R.); and the Grant-in-Aid for Scientific Research [16K11478] research grant for OBT research center from Kyushu University (to Z.W.).

V.H. and G.H. have equity positions at American Life Science Pharmaceuticals (ALSP) and are founders of ALSP. V.H. is an advisor to ALSP. G.H. is vice president of research, corporate counsel, and member of the board of directors at ALSP. V.H.'s conflict has been disclosed and is managed by her employer, the University of California, San Diego. No other author has an actual or perceived conflict of interest with the contents of this article.

dx.doi.org/10.1124/pharmrev.121.000527.

B.	Cathepsin B in Hippocampal Cell Death and Neuroinflammation in Hypoxia/Ischemia	623
C.	Cathepsin B in Brain Neuronal Cell Death in Epilepsy	623
D.	Cathepsin B and Cathepsin S in Multiple Sclerosis	624
E.	Cathepsin B in Inflammatory Pain	624
F.	Cathepsin B in Tolerance with Chronic Opioid Use	625
G.	Cathepsin B in Memory Deficits in Aging	625
H.	Cathepsin B in Memory Deficits, Neuroinflammation, and Amyloid- $\beta$ in Chronic Periodontitis-Associated Alzheimer's Disease	626
I.	Cathepsin B in Memory Deficits and Amyloid- $\beta$ in Transgenic Human Amyloid Precursor Alzheimer's Disease Models	627
1.	Transgenic Human Amyloid Precursor Protein Used in Cathepsin B Knockout Alzheimer's Disease Models Differ in the $\beta$ -Secretase Site Sequence, Amyloid Precursor Protein Isoform, and Gene Construct	627
2.	Major Cathepsin B Dependency of Memory Deficits and Amyloid- $\beta$ in Human Amyloid Precursor Protein with Wild-Type $\beta$ -Secretase Site Sequence and Amyloid Precursor Protein Isoform 695 Alzheimer's Disease Models, Representative of Most Alzheimer's Disease Patients	629
3.	Major Cathepsin B Dependency of Pyroglutamate Amyloid- $\beta$ in Human Amyloid Precursor Protein with Wild-Type $\beta$ -Secretase Site Sequence and Amyloid Precursor Protein Isoform 695 Alzheimer's Disease Model	631
4.	Minor Cathepsin B Dependency of Amyloid- $\beta$ Degradation in Human Amyloid Precursor Protein with Wild-Type $\beta$ -Secretase Site Sequence and Amyloid Precursor Protein Isoforms 751/770 Alzheimer's Disease Model	631
5.	Differences in Cathepsin B Dependency of Amyloid- $\beta$ in Human Amyloid Precursor Protein with Wild-Type $\beta$ -Secretase Site Sequence Alzheimer's Disease Models Likely Due to Different Isoforms or Constructs	632
6.	No Cathepsin B Dependency of Memory Deficits and Amyloid- $\beta$ in Human Amyloid Precursor Protein with Swedish Mutant $\beta$ -Secretase Site Sequence Models, Representative of Rare Familial Alzheimer's Disease Patients	632
J.	The Consilience of Aging, Chronic Periodontitis-Associated Alzheimer's Disease, and Transgenic Alzheimer's Disease Data Are that Memory Deficits Are Cathepsin B Dependent, which Provides Rationale for Cathepsin B Inhibitor Development	632
IX.	Cathepsin B Upregulation Is a Common Response in Neurologic Disorders and Causes Cellular Pathology by Multiple Specific Mechanisms	633
X.	Summary and Conclusion: Cathepsin B Knockout Data Validates Cathepsin B as a Drug Target for Development of Cathepsin B Inhibitors as Potentially New Therapeutics for Neurologic Disorders	633
XI.	Significance	634
	Authorship Contributions	634
	References	634

**Abstract**—Cathepsin B (CTSB) is a powerful lysosomal protease. This review evaluated *CTSB* gene knockout (KO) outcomes for amelioration of brain dysfunctions in neurologic diseases and aging animal models. Deletion of the *CTSB* gene resulted in significant improvements in behavioral deficits, neuropathology, and/or biomarkers in traumatic brain injury, ischemia, inflammatory pain, opiate tolerance, epilepsy, aging, transgenic Alzheimer's disease (AD), and periodontitis AD models as shown in 12 studies. One study found beneficial effects for double *CTSB* and

cathepsin S KO mice in a multiple sclerosis model. Transgenic AD models using amyloid precursor protein (APP) mimicking common sporadic AD in three studies showed that *CTSB* KO improved memory, neuropathology, and biomarkers; two studies used APP representing rare familial AD and found no *CTSB* KO effect, and two studies used highly engineered APP constructs and reported slight increases in a biomarker. In clinical studies, all reports found that *CTSB* enzyme was upregulated in diverse neurologic disorders, including AD in which elevated *CTSB* was

**ABBREVIATIONS:** A $\beta$ , amyloid-beta; AD, Alzheimer's disease; AGE, advanced glycation end; ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; CA-074, L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl-L-proline; CCI, controlled cortical impact; CFA, complete Freund's adjuvant; CgA, chromogranin A; CNS, central nervous system; CSF, cerebrospinal fluid; CTSB, cathepsin B; EAE, experimental autoimmune encephalomyelitis; EPM1, progressive myoclonus epilepsy of the Unverricht-Lundborg type; ESC, embryonic stem cells; FAD, familial Alzheimer's disease; hAPP, human amyloid precursor protein; HI, hypoxia/ischemia; HIV, human immunodeficient virus; ICP, intracranial pressure; IDUA,  $\alpha$ -L-iduronidase; IL, interleukin; KO, knockout; KWE, keratolytic winter erythema; Lon, London mutation of amyloid precursor protein; MPS 1, mucopolysaccharidosis type I; MS, multiple sclerosis; NF- $\kappa$ B, nuclear factor  $\kappa$ B; NLRP3, domains containing protein 3; PBBI, penetrating ballistic-like brain injury; PDGF, platelet derived growth factor; PgLPS, *Porphyromonas gingivalis* lipopolysaccharide; pGlu-A $\beta$ , pyroglutamate amyloid-beta; PPK, palmoplantar keratoderma; PS1, presenilin 1; QC, glutaminyl cyclase; Swe, Swedish mutation of amyloid precursor protein; TBI, traumatic brain injury; TNF $\alpha$ , tumor necrosis factor alpha; WT, wild-type.

positively correlated with cognitive dysfunction. In a wide range of neurologic animal models, CTSB was also upregulated and not downregulated. Further, human genetic mutation data provided precedence for CTSB upregulation causing disease. Thus, the consilience of data is that *CTSB* gene KO results in improved brain dysfunction and reduced pathology through blockade of CTSB enzyme upregulation that causes human neurologic disease phenotypes. The overall findings provide strong support for CTSB as a rational drug target and for CTSB inhibitors as therapeutic candidates for a wide range of neurologic disorders.

**Significance Statement**—This review provides a comprehensive compilation of the extensive data on the effects of deleting the cathepsin B (*CTSB*) gene in neurological and aging mouse models of brain disorders. Mice lacking the *CTSB* gene display improved neurobehavioral deficits, reduced neuropathology, and amelioration of neuronal cell death and inflammatory biomarkers. The significance of the compelling CTSB evidence is that the data consilience validates CTSB as a drug target for discovery of CTSB inhibitors as potential therapeutics for treating numerous neurological diseases.

## I. Introduction

Evidence for the role of the cysteine protease cathepsin B (CTSB) in neurologic diseases has been extensively investigated and supported by *CTSB* gene knockout (KO) studies in mouse models of brain disorders. These animal model studies address the role of CTSB upregulation, observed in human patients with neurologic diseases, by evaluating the behavioral, pathologic, and biomarker outcomes of *CTSB* gene KO in disease models. This review compiles and analyzes these *CTSB* gene KO data, showing that the absence of the CTSB protease results in improved behavioral deficits, amelioration of neuropathology, and regulation of biomarkers in mouse models of epilepsy, multiple sclerosis, traumatic brain injury, hypoxia/ischemia, tolerance to chronic opioid use, inflammatory pain, aging, Alzheimer's disease (AD), and chronic periodontitis-associated AD.

This review includes information on CTSB neurobiology, describes gene KO strategies for drug target validation and drug discovery, and discusses advantages and limitations of gene KO studies. This CTSB knowledge is used for elucidating the mechanistic roles of lysosomal CTSB in cell death and inflammation in such neurologic disease mouse models.

The consilience of the *CTSB* KO data in mouse models of neurologic disorders is that *CTSB* KO results in improvements in behavioral deficits, pathology, and dysregulated biomarkers compared with sufficient wild-type (WT) mice. Notably, *CTSB* KO in normal mice are generally healthy, fertile, and indistinguishable from WT mice. These significant results demonstrating CTSB-dependent mechanisms in models of brain disorders provide support for the proposition that inhibiting CTSB proteolytic activity is a logical therapeutic approach for such neurologic diseases.

## II. Cathepsin B is Elevated in Human Neurologic Disorders

Clinical findings show that CTSB levels are increased in many neurologic conditions, including several neurodegenerative diseases (Table 1). In AD, CTSB protein levels in the brain temporal cortex from patients with AD were

80% higher than that of age-matched controls (Batkulwar et al., 2018). AD brain autopsy samples showed that high CTSB protein concentration and enzymatic activity are abnormally localized at amyloid brain plaques (Cataldo and Nixon, 1990), although no difference in CTSB activity was reported for homogenized AD frontal cortex tissue (Mantle et al., 1995). Serum and plasma CTSB protein levels were 50% higher in AD patients relative to age-matched controls (Sundelöf et al., 2010; Sun et al., 2015). Importantly, in patients with AD, high serum CTSB levels were strongly correlated with cognitive dysfunction (Sun et al., 2015). Interestingly, blood monocytes and lymphocytes from patients with AD had about 50% less CTSB protein than those from controls (Tiribuzi et al., 2014), suggesting that a redistribution of CTSB from such cellular to extracellular compartments may occur. Cerebrospinal fluid (CSF) CTSB protein levels from patients with AD were significantly higher when analyzed by proteomic methods (Zhang et al., 2005) and appeared higher when assayed by Western immunoassays (Sundelöf et al., 2010; Armstrong et al., 2014), but CSF CTSB activity was not different from controls (Nagai et al., 2000). However, evaluation of the stability of CTSB activity in postmortem samples is necessary since it is known that CTSB has a finite period of stability at extracellular neutral pH (Yoon et al., 2021).

In chronic periodontitis linked to AD, serum CTSB levels were 43% higher relative to controls (Rong et al., 2020). In addition, the higher levels of serum CTSB in these patients correlated with reduced minimal state exam scores that measure cognitive function. Thus, patients with chronic periodontitis and AD display elevated serum CTSB that correlates with cognitive dysfunction.

In human immunodeficient virus- (HIV) associated neurocognitive disorders, elevated CTSB was observed in hippocampus and basal ganglia brain regions (Rodriguez-Franco et al., 2012). Furthermore, monocytes from plasma of patients with HIV-associated dementia showed higher CTSB levels compared with controls (Rodriguez-Franco et al., 2012; Cantres-Rosario et al., 2013).

Patients with amyotrophic lateral sclerosis (ALS) displayed a threefold elevation of CTSB expression

TABLE 1  
Elevation of cathepsin B in patients with neurologic disorders

Clinical Condition	Biofluid or Tissue	CTSB Regulation	Features	Reference
AD	Brain cortex	↑	CTSB protein increased by 18-fold	Batkulwar et al., 2018
AD	Brain	↑	High CTSB protein and proteolytic activity abnormally localized at amyloid plaques in brain	Cataldo and Nixon, 1990
AD	Serum	↑	Increased CTSB correlates with cognitive deficits	Sun et al., 2015
AD	CSF	↑	Increased CTSB protein	Sundelof et al., 2010; Armstrong et al., 2014
AD	CSF	↑	Increased CTSB protein in AD analyzed by proteomics	Zhang et al., 2005
AD	Plasma	↑	Elevated CTSB protein in mild and severe AD by 50%–80% above controls	Morena et al., 2017
Periodontitis linked to AD	Serum	↑	Increased CTSB levels by 43%	Rong et al., 2020
HIV	Brain and plasma monocytes	↑	Elevated CTSB	Rodriguez-Franco et al., 2012; Cantres-Rosario et al., 2013
ALS	Spinal cord	↑	Increased CTSB expression and protein	Kikuchi et al., 2003; Dangond et al., 2004; Offen et al., 2009; Saris et al., 2013
Severe trauma	Plasma	↑	CTSB activity was elevated 5- to 6-fold in severe trauma leading to organ failure	Assfalg-Machleidt et al., 1990; Jochum et al., 1993
Traumatic brain injury	CSF	↑	Elevated CTSB protein by twofold	Boutte et al., 2020
Multiple trauma	Plasma	↑	Elevated CTSB associated with trauma and sepsis	Jochum et al., 1993
Vascular pathology	Brain vascular endothelium	↑	Elevated CTSB levels	Aoki et al., 2008
Guillain-Barre syndrome	CSF	↑	Elevated CTSB activity	Nagai et al., 2000
Aging	CSF	↑	Increased CTSB protein correlated positively with age	Nilsson et al., 2013

(Saris et al., 2013) in spinal tissue compared with controls (Dangond et al., 2004; Offen et al., 2009). Moreover, CTSB protein levels were higher and abnormally distributed in dying neurons from the anterior horn of patients with ALS relative to controls, suggesting that CTSB may be associated with neuronal cell death (Kikuchi et al., 2003).

CTSB activity or protein levels were significantly elevated in CSF from patients with Guillain-Barre syndrome, chronic demyelinating polyneuropathy, and multiple sclerosis (MS) neuroinflammatory disorders relative to controls (Nagai et al., 2000). Also, levels of cystatin C, an endogenous inhibitor of CTSB, were reduced in these inflammatory neurologic diseases, consistent with elevated CTSB activity. These findings suggest that CTSB activity may be closely involved in the pathophysiology of these inflammatory neurologic diseases.

Patients with polytrauma, which can include patients with traumatic brain injury (TBI), exhibit neurologic complications and have elevated CTSB (Assfalg-Machleidt et al., 1990; Jochum et al., 1993). Plasma CTSB activity was significantly increased at one day after trauma injury and remained at higher levels at the third day to two weeks post-trauma. The sixfold elevation in plasma CTSB

activity correlated with the severity of injury and clinical outcomes of fatal organ failures. Related to polytrauma, in patients with TBI, CTSB protein levels in the CSF were increased twofold compared with controls (Boutte et al., 2020). In multiple trauma with sepsis, plasma CTSB was increased (Jochum et al., 1993). Brain aneurysm trauma resulted in elevated CTSB protein levels within the brain vascular endothelial layer at the aneurysm site (Aoki et al., 2008).

These human clinical data show that numerous neurologic disorders are associated with increased CTSB. Notably, several studies showed a correlation between elevated CTSB and clinical outcomes including cognitive dysfunction of AD and organ failures in trauma. These data provide support for the hypothesis that inhibition of CTSB may be a logical approach for treating such brain disorders.

### III. Cathepsin B Genetic Mutations Increase Cathepsin B and Cause Human Diseases

Keratolytic winter erythema (KWE) is an orphan skin disease (Ramsay et al., 2019) caused by a mutation upstream of the *CTSB* gene located at an intergenic region containing an enhancer element known

TABLE 2  
Elevation of Cathepsin B in Animal Models of Neurologic Disorders

Animal Model	Species, Age	CTSB Regulation	CTSB mRNA, Protein, or Activity	Tissue	References
Alzheimer's disease, 5XFAD model	Mouse, 12 months	↑	Elevated gene expression	Brain	Bouter et al., 2014
Alzheimer's disease, APPSwe/PS1	Mouse, 12 months	↑	Increased protein	Brain	Sun et al., 2015
Periodontitis, Alzheimer's disease	Mouse, 12 months	↑	Increased protein	Hippocampus brain region	Wu et al., 2017
TBI trauma	Mouse, 3–5 months, and rat, 2–3 months	↑	Elevated mRNA, protein and proteolytic activity	Brain	Natale et al., 2003; Zhang et al., 2006; Luo et al., 2010; Sun et al., 2013; Hook et al., 2014a; Boutte et al., 2020
Trauma spinal cord contusion	Rat, 2–3 months	↑	Increased mRNA, protein, and activity	Brain	Ellis et al., 2004, 2005
Trauma surgery	Mouse, ~3 months	↑	Elevated activity in extracellular matrix	Intestine	Vreemann et al., 2009
Subarachnoid hemorrhage	Rat, ~3–4 months	↑	Increased protein	Brain	Yu et al., 2014; Wang et al., 2015
Brain aneurysm	Rat, 2 months at time of injury, and 5 months for analysis	↑	Elevated mRNA and activity	Cerebral aneurysm walls	Aoki et al., 2008
ALS (amyotrophic lateral sclerosis)	Mouse, 2–4 months	↑	Increased mRNA	Spinal cord motoneurons	Ferraiuolo et al., 2007; Offen et al., 2009
Excitatory epilepsy	Rat, ~1 month	↑	Increased protein	Brain and spinal cord	Ni et al., 2013
Excitotoxicity, Huntington's disease	Rat, 2–3 months	↑	Elevated protein	Brain	Wang et al., 2006
Ischemia, acute	Rat, 2–3 months	↑	Elevated protein and activity	Brain	Tsubokawa et al., 2006
Ischemia	Monkey, adult, and rat, 2–3 months	↑	Increased protein and activity	Brain	Seyfried et al., 1997; Yamashima et al., 1998; Tsuchiya et al., 1999; Tsubokawa et al., 2006
Hypoxia/ischemia, neonatal	Mouse, neonatal	↑	Increased mRNA and enzyme protein	Microglia hippocampus	Ni et al., 2015
Meningitis brain infection	Mouse <sup>a</sup>	↑	Increased proteolytic activity	Human THP-1 cells	Hoegen et al., 2011
Sepsis infection	Rat, 2 months or 1 month	↑	Increased proteolytic activity	Skeletal muscle	Ruff and Secrist, 1984; Hummel et al., 1988
Inflammation, aging	Mouse, 12 months, and 2, 10, 20 months	↑	Increased mRNA and protein	Brain	Wu et al., 2017; Ni et al., 2019
Inflammatory pain	Mouse, ~1 month	↑	Elevated protein	Spinal cord	Sun et al., 2012

<sup>a</sup>Age not indicated.

to be active in skin development (Oti et al., 2016; Ngungcu et al., 2017). Duplication of the enhancer results in the mutation causing overexpression of CTSB in the skin stratum granulosum of affected individuals. South African and Norwegian KWE families each carry different duplications that overlap in the enhancer region. Environmental conditions, such as cold winter weather and certain physiologic conditions, trigger the enhancer element to upregulate CTSB expression resulting in erythema and hyperkeratosis.

Palmoplantar keratoderma (PPK) is a heterogeneous group of keratinization skin disorders classified as sporadic or genetically inherited forms, with the latter caused by a plethora of mutations in many genes (reviewed in Schiller et al., 2014). A genetic analysis of the *CTSB* gene was conducted in a patient with PPK who presented with a KWE-like phenotype, finding a mutation in the *CTSB* gene that caused the

disease (Mohamad et al., 2021). A family pedigree analysis suggested an autosomal dominant mode of gene inheritance in the disease, and gene sequencing found a single nucleotide mutation in the *CTSB* gene that resulted in substitution of a methionine residue for valine at position 255 at the active site. The mutant CTSB was found to have 10% higher *in vitro* activity relative to normal CTSB. The authors concluded that the gain in CTSB activity resulted from the *CTSB* gene mutation of the patient with PPK.

Mutation of *CTSB* may be associated with pancreatitis. CTSB activity is involved in the initiation of acute pancreatitis in an animal model (Halangk et al., 2000). A significantly higher SNP (single nucleotide polymorphism) allele frequency was found in Southern Indian patients with tropical calcific pancreatitis relative to controls (Mahurkar et al., 2006). That mutation caused a leucine to valine substitution at position 26 in the propeptide region of CTSB, which may alter CTSB

maturation. However, a subsequent study evaluated the position 26 mutation in European patients with idiopathic chronic pancreatitis and found no difference in the allele frequency compared with controls and other ethnic groups, indicating that the mutation was not a susceptibility factor for pancreatitis in the population of patients studied (Weiss et al., 2007). The findings suggest that *CTSB* gene mutations of pancreatitis may vary in patient groups of different ethnic backgrounds.

The *CTSB* gene mutations identified thus far have resulted in increased CTSB. On the other hand, we are not aware of a human disease in which a CTSB loss of function mutation causes a disease. Genetic mutations also occur in other cathepsin proteases, including cathepsin A, cathepsin D, cathepsin F, cathepsin K, cathepsin C, and cathepsin H, and cause rare diseases (Ketterer et al., 2017).

#### IV. Cathepsin B Is Elevated in Animal Models of Neurologic Diseases

Brain CTSB is elevated in a wide variety of neurologic animal models, including AD, TBI, ischemia, inflammatory injury, ALS, and epilepsy (Table 2). This suggests that elevated CTSB in the brain commonly occurs in neurologic pathologies.

Transgenic AD mouse models have been developed that overexpress human amyloid precursor protein (APP) and presenilin 1 (PS1) containing familial mutations found in people genetically predisposed to develop some of the pathology and behavioral deficits observed in patients with AD (Parent and Thinnakaran, 2010; Sasaguri et al., 2017). CTSB expression is elevated by 32% in the 5X familial Alzheimer's disease (FAD) mouse model, which expresses three APP mutations consisting of APP KM670/671NL (Swedish mutation), APP 716V (Florida mutation), and APP V171I (London mutation) combined with two human PS1 mutations consisting of PSEN1 M146L and PSEN1 L286V (Bouter et al., 2014). In the APPSwe/PS1 AD mouse model, expressing human APP with the Swedish FAD mutation and PS1 with FAD mutations, CTSB enzyme levels were increased by 50% in the cortex and hippocampus brain regions (Sun et al., 2015).

In TBI models, such as the severe open skull controlled cortical impact (CCI) mouse, penetrating ballistic-like brain injury (PBBI) rat model, and closed head weight drop mouse and rat models, CTSB in the brain was elevated in its RNA (Natale et al., 2003) and protein levels (Zhang et al., 2006; Luo et al., 2010; Boutte et al., 2020), as well as its proteolytic activity (Hook et al., 2014a; Boutte et al., 2020). These TBI-induced elevations in CTSB occurred in various brain regions, including the hippocampus, for various times postinjury from two days to one month and was accompanied by cognitive deficits or

neuromuscular dysfunction. In a moderate closed head weight drop TBI rat model, increased CTSB was observed by histologic expression that occurred in the hippocampus and numerous other brain regions (Martinez-Vargas et al., 2014). In a CCI TBI mouse model, brain CTSB activity was significantly elevated by 64% at two hours after injury relative to controls (Hook et al., 2014a). In a severe PBBI TBI rat model, CTSB levels and activity were significantly increased in the cortex and hippocampus at 3–7 days after PBBI (Boutte et al., 2020). In a weight drop TBI mouse model, brain CTSB was elevated at 6 hours after injury and peaked at 2 days post-trauma, with continued elevation for up to one week (Luo et al., 2010). In a rat TBI model, brain CTSB was elevated within one hour after injury, which maximally increased at 8 days postinjury and remained elevated for more than one month (Zhang et al., 2006). These models of moderate to severe TBI together demonstrate that a rapid and sustained CTSB increase can occur after trauma.

Ischemia and inflammatory brain injuries in animal models also resulted in elevated CTSB. For example, increased CTSB of 2- to 3-fold above controls occurred in brains of acute and chronic rat and nonhuman primate ischemic models (Seyfried et al., 1997; Yamashima et al., 1998; Tsuchiya et al., 1999; Tsubokawa et al., 2006). Inflammation due to bacterial meningitis (Hoegen et al., 2011), sepsis (Ruff and Secrist, 1984; Hummel et al., 1988), neuroinflammation (Terada et al., 2010; Wu et al., 2017; Ni et al., 2019), and inflammatory pain (Sun et al., 2012) resulted in elevation of brain CTSB that was 50% to sixfold above controls.

In ALS models, CTSB expression was elevated by threefold in the spinal cord (Offen et al., 2009). CTSB was also upregulated in patients with ALS (Saris et al., 2013). In animal models of epilepsy, CTSB protein levels are elevated (Ni et al., 2013). Furthermore, in excitotoxicity related to Huntington's disease, cathepsin B is elevated (Wang et al., 2006). These findings indicate association of elevated brain CTSB in multiple animal models of neurologic diseases.

#### V. Cathepsin B Neurobiology

##### A. Cathepsin B Is a Cysteine Protease

*1. Cathepsin B Protease Activity.* CTSB is a lysosomal protease that cleaves peptide bonds of proteins and peptides to generate smaller fragments that often have distinct biologic functions. CTSB is a cysteine protease based on its reactive cysteine residue within its active site. CTSB belongs to the CA clan of cysteine proteases (Rawlings et al., 2014) and is a member of the C1A family whose members are closely related to papain (cysteine protease from papaya) and includes the cysteine cathepsins B, C, F, H, K, L, O, S, V, W,

and Z (also called cathepsin X). In addition to the cysteine cathepsins, cathepsins include aspartyl proteases cathepsin D and cathepsin E and the serine proteases cathepsin A and cathepsin G (Mort, 2004; Turk et al., 2012; Hsu et al., 2018).

CTSB has been extensively studied since its discovery in 1939 (Fruton and Bergmann, 1939). Forty-four years later, the first amino acid sequences of CTSB were determined (Takio et al., 1983), followed shortly thereafter by the first gene sequences (Chan et al., 1986) and then the first X-ray crystal protein structure (Musil et al., 1991). Most proteases have either endopeptidase activity, which cleaves peptide bonds within the polypeptide substrate, or exopeptidase activity, which removes amino-terminal or carboxy-terminal residues. CTSB is unusual in having both endopeptidase (Mort, 2004) and exopeptidase activities (Aronson and Barrett, 1978; Takahashi et al., 1986) regulated by its occluding loop structure at the active site (Illy et al., 1997).

Endopeptidases and exopeptidases recognize specific amino acids flanking the cleaved peptide bond (Schechter and Berger, 1967). When acting as an endopeptidase, CTSB prefers to cleave peptide bonds with an adjacent positively charged arginine or lysine amino acid (P1 position) and a bulky hydrophobic or arginine amino acid at the next distal position (P2 position) (Mort, 2004; Gosalia et al., 2005; Choe et al., 2006; Yoon et al., 2021). CTSB and other proteases possess selectivity for cleavage preferences that may be unique or overlapping.

CTSB protease activity in biologic samples is typically assayed with fluorogenic peptide-AMC substrates that mimic peptide bond cleavages to generate free, fluorescent AMC (7-amino-4-methylcoumarin) that is quantitatively measured. A typical CTSB fluorogenic substrate used in the field is Z-Phe-Arg-AMC, where Z is an N-terminal carboxybenzyl blocking group (Murata et al., 1991; Ruzza et al., 2006). But such a substrate can be cleaved by multiple proteases in addition to CTSB (Hwang et al., 2005). Therefore, a cautionary note regarding such fluorogenic activity data is that such results can indicate multiple protease activities in addition to CTSB. Thus, in heterogeneous tissue samples containing many proteases, CTSB protease activity is best identified with use of a specific inhibitor of CTSB, CA-074 (L-3-*trans*-(Propylcarbamyl)oxirane-2-carbonyl)-L-proline (Towatari et al., 1991). Activity that is inhibited by CA-074 is designated CTSB activity (Boutté et al., 2020). It is also noteworthy that CTSB requires a reduced state of the active site cysteine for its proteolytic activity.

**2. Cathepsin B Maturation.** Active CTSB is generated through a maturation process involving gene transcription, translation, and conversion of the inactive pro-CTSB to mature active CTSB (Fig. 1). Human *CTSB* is encoded as a single gene on


chromosome 8 at position p22-23.1 (Fong et al., 1992), consisting of >21 kilobases and contains 12 exons (Gong et al., 1993). Mouse *CTSB* is also a single gene containing about 20 kilobases, 10 exons, and nine introns on chromosome 14 at position 33.24 (Qian et al., 1991; Deussing et al., 1997). Human and mouse *CTSB* nucleic acid sequences encoding the active form of the protease have 82% homology (Chan et al., 1986). In normal human tissues, CTSB mRNAs consist of 2.3 and 4.0 kilobase transcripts, which differ in the untranslated regions (Gong et al., 1993), with the normal brain containing primarily the 2.3 kilobase mRNA form (Sivaparvathi et al., 1995).

CTSB mRNA is translated into its preproenzyme of 339 amino acids, which is cotranslationally processed to remove the N-terminal signal peptide to result in proCTSB. The proenzyme is then glycosylated in the rough endoplasmic reticulum, translocated to the Golgi apparatus, and undergoes trafficking to the lysosome (reviewed in Mort 2004; Katunuma, 2010; Turk et al., 2012). The proenzyme undergoes autohydrolysis to form the shorter mature CTSB (~27 kDa), which can be further processed into a double chain form consisting of heavy (~22 kDa) and light (~5 kDa) chains covalently linked by disulfide bonds (Fig. 1) (Hook et al., 2020). Both the mature and double chain forms are enzymatically active.

### *B. Cathepsin B in Brain and Subcellular Organelles*

In normal human and rodent brains, CTSB protein is concentrated in neuronal cells of the cortex, hippocampus, neostriatum, and cerebellum (Howie et al., 1985; Bernstein et al., 1990; Nakanishi et al., 1994). In the human brain, CTSB gene expression is consistently and highly expressed in 16 brain regions from early prenatal to young adult and is one of the four most abundantly transcribed brain cathepsins (Hsu et al., 2018). A view of *CTSB* gene expression in the mouse brain indicates its high abundance in hippocampus and cortex, regions involved in memory and cognitive functions (Fig. 2) (Hook et al., 2015). Brain tissues release CTSB to the cerebrospinal fluid (CSF), and elevated CTSB in CSF occurs with increasing age (Nilsson et al., 2013).

Within cells, CTSB is normally sequestered primarily in lysosomes but is also found in vesicles of the regulated secretory pathway (Tu et al., 2008). CTSB in lysosomes participates in protein degradation to maintain cellular homeostasis, functioning at the acidic pH within lysosomes (Hanewinkel et al., 1987; Mort and Buttle, 1997; Jung et al., 1999). The CTSB concentration within lysosomes is among the highest compared with other cathepsin enzymes of cathepsins L and H (Katunuma, 2010). CTSB resides in lysosomes together with other cysteine cathepsins (cathepsins C, F, H, K, L, O, S, V, W, and Z), aspartyl cathepsins D and E, serine cathepsins A and G, and other proteases, such as



**Fig. 1.** Maturation of CTSB: zymogen conversion to active CTSB. Mature, active CTSB is generated from its inactive zymogen that is converted to the active CTSB enzyme. Preprocathepsin B is generated from its mRNA and its N-terminal signal sequence (SP) is removed by signal peptidase to result in procathepsin B. Procathepsin B undergoes autoproteolysis to remove the propeptide (Pro) to generate the mature CTSB. CTSB may also undergo additional processing into light and heavy chains linked by disulfide bonds. Cys108 (\*) represents the active cysteine residue. These sequences of human CTSB were obtained from National Center for Biotechnology Information (NCBI) and UniProt databases.


legumain and tripeptidyl-peptidase, which together function in lysosomal protein degradation (Hsu et al., 2018).

Autophagosomes are present in cells for degradation of accumulated proteins, damaged organelles, and microorganisms via a process called macroautophagy (Xie and

Klionsky, 2007; Uchiyama et al., 2008). Lysosomes fuse with autophagosomes to provide the proteases needed for protein degradation, including CTSB as a key protease in autophagy catabolism.

Secretory lysosomes are another subcellular organelle where CTSB resides (Tu et al., 2008). Secretory lysosomes

### Cathepsin B Expression in Mouse Brain Regions



**Fig. 2.** CTSB expression in mouse brain regions. (A) Nissl stain of mouse brain. A coronal section of adult mouse brain was subject to Nissl staining (from the Allen Brain Institute (<http://www.brain-map.org/>)). (B) CTSB mRNA expression in mouse brain. In situ hybridization of mouse brain sections was conducted with antisense mRNA to cathepsin B. The relative levels of CTSB mRNA expression are shown at high levels by shades of yellow to red (yellow, highest express); lower relative expression levels are shown in green to blue (blue, lowest level of expression). CTSB displays high expression of the hippocampus and cortex regions (adapted from Hook et al., 2015, DOI: 10.3389/fneur.2015.00178 indicating Frontiers as the original publisher).



function in protein degradation and as secretory vesicles for release of its contents, including CTSB to the extracellular environment (Blott and Griffiths, 2002). In the mammalian central nervous system, astrocytes contain secretory lysosomes (Verkhatsky et al., 2016), which can secrete active CTSB in response to a neurotoxin (Verderio et al., 2012). Hippocampal pyramidal neurons also secrete CTSB via lysosomal exocytosis in response to back-propagating action potentials (Padamsey et al., 2017).

CTSB functions in nuclei have been shown by several studies. Such reports have shown that nuclear CTSB functions in, for example, cell viability (Bestvater et al., 2005), thyroid carcinoma (Tedelind et al., 2010), sirtuin degradation in microglia nuclei (Meng et al., 2020, and mitotic chromosome segregation (Hämälistö et al., 2020).


Neurons and endocrine cells contain regulated secretory vesicles that contain neurotransmitters and hormones that are released in response to stimulation by electrical action potentials and receptors (Lin and Salton, 2013). In the central nervous system (CNS), electrical signals activate neurons to secrete chemical neurotransmitters from secretory vesicles at synapses for neurotransmission. CTSB is present in regulated secretory vesicles of pancreatic acinar (Kukor et al., 2002), pancreatic beta (Kuliawat et al., 1997), kidney juxtaglomerular (Wang et al., 1991), neuroendocrine adrenal cells (Hook and Reisine, 2003; Jiang et al., 2021), and neuronal cells (Klein et al., 2009).

In the extracellular environment, CTSB is able to degrade protein scaffolds, such as fibrinogen (Gabrijelcic et al., 1988), collagen (Maciewicz et al., 1990; Li et al., 2016), and the basement membrane components of laminin, fibronectin, and collagen type IV (Buck et al., 1992). Furthermore, extracellular CTSB damages tight junctions of endothelial cells, resulting in permeability of the vessel wall (Wang, et al., 2016). Thus, extracellular CTSB is particularly dangerous in causing biologic damage.

### C. Cathepsin B Lysosomal Leakage Causes Inflammation and Cell Death in Neurologic Disorders

CTSB is virtually absent in cytosol of normal healthy cells that sequester CTSB in lysosomes, which protects cytosolic proteins from CTSB degradation (Chiappini et al., 2015). However, in numerous neurologic disease conditions, lysosomal leakage allows CTSB to move into the cytosol where it triggers apoptosis and activates production of proinflammatory cytokines that participate in neurodegeneration and behavioral deficits (Fig. 3). Cytosolic CTSB may also induce necrotic cell death, causing inflammatory reactions at the necrotic site. CTSB in the cytosol induces assembly of the NACHT, LRR, and PYD domains containing protein 3 (NLRP3) inflammasome whose cell death-inducing interleukin-1 converting enzyme (caspase-1) matures the potent proinflammatory interleukin (IL)-1 $\beta$ ,

### Cathepsin B Lysosomal Leakage Leads to Cell Death and Neuroinflammation in Behavioral Deficits and Neurodegeneration of Neurological Disorders



**Fig. 3.** Cathepsin B lysosomal leakage leads to cell death and neuroinflammation in behavioral deficits and neurodegeneration of neurologic disorders. CTSB is normally located within lysosomes. In numerous brain trauma and neurodegenerative disease conditions, lysosomal membrane permeabilization (LMP) results in translocation of CTSB to the cytosol. It is hypothesized that pathogenic cytosolic CTSB activates pathways for cell death and inflammation that result in behavioral deficits and neurodegeneration pathology. CTSB in the cytosol is involved in proteolysis to generate proapoptotic tBid and degrades antiapoptotic Bcl-xL to mediate cell death (Repnik and Turk, 2010; de Castro et al., 2016). Cytosolic CTSB activates production of IL-1 $\beta$  and IL-18 pro-inflammatory factors (Hentze et al., 2003; Bai et al., 2018; Campden and Zhang, 2019) that are released through the gasdermin D pore (GSDMD) (Tsuchiya et al., 2021). Cell death and inflammation result in neurodegeneration and behavioral deficits of numerous neurologic disease conditions.

(Campden and Zhang, 2019). Further detrimental effects of cytosolic CTSB are the induction of tumor necrosis factor alpha (TNF $\alpha$ ) and oxidative cell stress (reviewed in Hook et al., 2020). Based on those mechanisms, cytosolic CTSB participates in the pathogenesis of many neurologic conditions (Hook et al., 2020).

Importantly, at the neutral pH condition of the cytosol, CTSB possesses proteolytic activity (Mort et al., 1984; Linebaugh et al., 1999; Yoon et al., 2021). This contrasts with many other lysosomal proteases that are only active at the acidic pH within lysosomes and are not active at the neutral pH of the cytosol (Turk et al., 2012; Yoon et al., 2021). CTSB activity in the cytosol cleaves substrates that lead to activation of cell death and inflammation (Fig. 3). In addition, CTSB also translocates to the nucleus where it degrades sir-tuins and promotes aging (Meng et al., 2020). The precise cytosolic substrates degraded by CTSB are not yet well-characterized. It will be important in future studies to define the cytosolic CTSB-mediated pathways of cell death and inflammation in neurodegeneration.

#### D. Endogenous Inhibitors of Cathepsin B

Cysteine cathepsin protease activity is controlled *in vivo* by potent endogenous protease inhibitors consisting of cystatin type 1 (the stefins), cystatin type 2, and kininogens (reviewed in Turk and Bode, 1991). The cystatin type 1 family is composed of cystatin A and cystatin B, which reside primarily in the cytosol and nucleus of cells where they are the primary means for inhibiting unwanted lysosomal cysteine protease activity (Turk et al., 2002). In extracellular fluids, CTSB activity is controlled by cystatin C, which is a member of the cystatin 2 family. Human CSF and plasma cystatin C concentrations are 16,000- and 170-fold greater than that of their CTSB concentrations, respectively (Hook et al., 2015). CSF and plasma cystatin C concentrations reduce CTSB activity by half in 0.69 and 3.5 seconds, respectively (Abrahamson et al., 1986), showing that cystatin C is an effective CTSB inhibitor. As an example of the importance of endogenous inhibitors, loss of cystatin B inhibition causes a rare childhood form of epilepsy called Unverricht-Lundborg type (discussed in *section VIII.C* of this review) (Houseweart et al., 2003). Clearly, there is a considerable biologic investment made in endogenous inhibitors to control cytosolic and extracellular cysteine protease activity, including CTSB.

## VI. Gene Knockout Mice for Target Validation and Drug Discovery

### A. Mouse Gene Knockout Studies to Understand Mechanisms of Human Diseases

1. *Gene Knockout Approach.* The mouse (*mus musculus*) has been extensively used as a model for

studying human diseases for over a century. Mouse models of neurologic diseases provide a bridge for understanding the roles of genes that are dysregulated in human brain disorders with respect to behavioral dysfunctions and cellular mechanisms. Understanding of mechanisms participating in human disease pathogenesis has been advanced through investigation of transgenic mice with knockout of specific genes. The KO technology allows individual genes to be silenced and the biologic effects of the gene's absence can be evaluated in the living animal. Mario R. Capecchi, Martin J. Evans, and Oliver Smithies developed this technology for which they were awarded the Nobel Prize in 2007 (Hansen, 2007) with the first gene knockout studies published in 1990 (Koller et al., 1990; Zijlstra et al., 1990).

Mice are advantageous as models for human diseases since 99% of mouse genes have human homologs with a mean amino acid identity of 78.5% (Waterston et al., 2002). Also, mice share common mammalian processes for development, body formation, physiology, behavior, and diseases with humans. Mouse gene KO studies have advanced understanding of the biologic functions of numerous gene products (Palmiter and Brinster, 1985; Paigen, 2003).

Gene KO mice are generated from *in vitro* mouse embryonic stem cells (ESC). Briefly, homologous recombinant genes (which cannot be transcribed) are inserted into ESC at a predetermined location in the genome to thereby replace the gene at that position and prevent transcription of the targeted gene (reviewed in Mak, 2007). Hence, that gene is knocked out. The ESC with the modified, nonfunctional gene are selected and transferred into nonmodified mouse blastocysts, which are implanted into pseudopregnant mice. The resulting progeny contain the target gene in some cells but not others (chimeras); the progeny that carry the target gene in germ cells are selected for and bred to produce offspring in which the gene is inactivated in all tissues. A variant of this method, called gene trapping, was subsequently developed that allows larger numbers of genes to be replaced more rapidly by randomly inactivating genes (reviewed in Stanford et al., 2001). Both methods are used, and each has its advantages.

2. *Limitations and Controls for Gene Knockout Studies.* Use of gene knockout mice should consider limitations of the approach, which include developmental lethality, tissue specificity, genetic background effects, and passenger mutations. Such limitations can be minimized with appropriate controls that are important for interpretation of gene KO results. It is also important to assess gene knockout effects in both male and female genders of animals.

A limitation of gene knockout studies is that about 15% of the constitutive gene KO are developmentally

lethal, such that genetically altered homozygous embryos cannot develop into adult mice. In some cases, offspring having only one copy of the wild-type gene may be viable and can be studied. With respect to KO of mutant genes that are lethal, heterozygous offspring having one copy of the mutant gene may be viable for experimental studies.

Also, constitutive KO mice cannot be used to evaluate effects of deleting the protein in one particular tissue because the germline transmitted KO removes the protein from all tissues. Therefore, conditional KO approaches for deletion of the gene at a defined age or in a defined tissue are increasingly used in the field. Nonetheless, all *CTSB* KO studies described in this review have been made by constitutive KO models, and useful information on *CTSB* functions have resulted from those KO studies.

The animal's genetic background can affect outcomes of gene KO conditions. For example, commonly used inbred strains of mice exhibit differences in morphine and pain sensitivity (Mogil and Wilson, 1997; reviewed in Lariviere et al., 2001) as well as cognitive ability (Brooks et al., 2005). Moreover, substrains of the most commonly used strain C57BL/6 may exhibit behavioral differences (Bryant et al., 2008). It is, therefore, important to define the genetic background.

Another potential problem of gene KO studies is the issue of "passenger" mutations, consisting of unwanted genetic alterations that accompany the knockout modification that can confound outcome results (reviewed in Gerlai, 1996). Knockout mice are often congenic, which is to say they contain genetic material from another mouse strain. This occurs because the ESC and the blastocyst/mouse are often from different mouse strains. In the first decade of gene targeting in mice, 129 mouse strain ESC cells were implanted into the C57BL/6 blastocyst and mouse because C57BL/6 mice are easy to breed and well-characterized. The C57BL/6 mice with the gene deletion are repeatedly backcrossed to reduce the 129 gene pool by recombination, but segments of the 129 gene pool around the targeted gene locus usually remain because during meiosis the homologous recombination frequency for allelic exchange near the transgene is low. The passenger genes from the ESC cells can produce different proteins from that of the wild-type surrogate strain. An example of a passenger confound effect occurred in caspase-1 KO C57BL/6 mice that were generated with 129 ESC that resulted in no *mIL-1 $\beta$*  as expected but surprisingly reduced septic shock mortality in response to lipopolysaccharide treatment (Li et al., 1995). The genome of those animals was subsequently shown to contain a mutant strain 129 caspase-11 gene, which provided resistance to septic shock (Kayagaki et al., 2011). In another example, caspase-3 KO C57BL/6 mice produced using 129 ESC were also resistant to

septic shock mortality due to the strain 129 caspase-11 passenger gene (Vanden Berghe et al., 2013). There are over a thousand 129 strain genes, which diverged from the C57BL/6 strain sequence (Vanden Berghe et al., 2015) and 12 backcrosses over 2 years of breeding have been estimated to result in C57BL/6 mice with 1% 129 genes or about 300 129 genes (Festing, 1992). However, by now most newly generated KO strains are based on targeting ES cells derived from C57BL/6 mice, allowing for defined background genetics in the animal studies (Pettitt et al., 2009). Further, control studies can resolve confounding passenger effects, which include generating ESC in cells of the surrogate strain (e.g., Uccellini et al., 2020), conducting rescue experiments in which the functional gene is reinserted into the knockout, or generating "knock-in" mice in addition to the knockout mice (reviewed in Gerlai, 1996).

Gene knockout studies should assess whether similarities or differences occur for male and female genders. Neuropathological *CTSB* KO studies to date have not compared male and female genders (Table 3). It will be important to assess if gender effects may occur in *CTSB* KO mice since such effects have been shown to occur in models of anxiety (Czibere et al., 2011) and cholesterol (Wong et al., 2013).

## B. Gene Knockout Mice in Drug Discovery

**1. Drug Targets Assessed by Gene Knockout.** Gene knockout animals are a powerful tool for identifying potential drug targets. Knockouts of the druggable genome are particularly important for target validation. Genes of the druggable genome encode proteins having a function that can be pharmacologically affected and include genes encoding enzymes, receptors, transporters, channels, and secreted proteins. A review of KO mice for the top drug targets showed there is a strong correlation between phenotypes, mechanism of action, and utility of the associated therapeutics that have led to the conclusion that KO animals provide a path forward for the biopharmaceutical industry to discover next generation targeted therapeutics (Zambrowicz and Sands, 2003).

A large public effort by a pharmaceutical company to use gene knockout animals to identify drug targets has been achieved by Lexicon Pharmaceuticals in its Genome5000 campaign in partnered alliances (Tang et al., 2010; reviewed in Brommage et al., 2019). From 2001 to 2008, 4654 knockout animals of the druggable genome were created and data were published on 100 gene knockouts focusing on obesity and bone phenotypes. An example of a drug that resulted from this effort is XERMELO (telostriat), a treatment of carcinoid syndrome diarrhea caused by intestinal serotonin (reviewed in Rendell, 2019). Deletion of the serotonin-synthesizing gene tryptophan hydroxylase resulted in improved physiology of the

TABLE 3  
Cathepsin B Knockout Improves Behavioral Deficits in Animal Models of Neurologic Disorders

Cathepsin B Knockout in the Neurologic Disease Model Improves Outcomes		References	
Neurologic Disease Mouse Model, Age, Sex	Behaviors	Biomarkers	
Traumatic brain injury: controlled cortical impact mouse model, 15–28 weeks old, male	↓Neuromotor deficits	↓Proapoptotic Bax	Hook et al., 2014a
Hypoxia-ischemia: neonatal HI mouse model, neonatal, sex not specified	nd	↓NF- $\kappa$ B to reduce inflammatory cytokines	Ni et al., 2015
Epilepsy: EPML1, cystatin B KO mouse model, 2, 4, and 8 months old, sex not specified	No effect on seizures	nd	Houseweart et al., 2003
Multiple sclerosis: EAE mouse model, 8–10 weeks old, female	↑Clinical score, ↑ time of disease onset	↓Infiltrating immunologic cells, ↓antigen presentation	Allan and Yates, 2015
Inflammatory pain: CFA model, 5 weeks old, male	↓Allodynia behavioral test for pain	↓Microglia cell size morphology, ↓decreased microglia extensions	Sun et al., 2012
Tolerance to opioid: chronic morphine antinociceptive tolerance, 10 weeks old, male	Prevents opiate tolerance, ↓pain assessed by thermal hot plate test	↑Elevation in excitatory postsynaptic potential	Hayashi et al., 2014

nd, not determined.

carcinoid disease condition; as a result, small molecule inhibitors of tryptophan hydroxylase were developed for therapeutics. To our knowledge, the Genome5000 campaign has not published on *CTSB* KO animals.

Gene KO mouse approaches and resources are benefiting investigation of the mechanistic roles of specific genes, including *CTSB*, as candidate drug targets in human brain disorders modeled in transgenic models of neurologic diseases.

2. *On- and Off-Target Drug Effects Assessed in Gene Knockout Mice.* Gene KO animals can be advantageously used to evaluate the potential of candidate drugs for on- versus off-target effects. For example, if the drug targets inhibition of a particular gene product, then the candidate drug will result in no changes when administered to animals with KO of that target gene. Alternatively, effects of the drug in animals with KO of the target gene can indicate off-target effects.

Such inhibitor effects in target gene KO mice are useful for protease inhibitor drug candidates.

Analyses of drug effects in mice with KO of the target gene may reveal specific actions of the drug at the target, off-target effects, or a combination of on- and off-target effects. This approach has been used in *CTSB* and other cysteine cathepsin KO mice to evaluate an inhibitor's efficacy by on- and off-target effects (Hook et al., 2014b).

### VII. Cathepsin B Knockout Mice Are Generally Indistinguishable from Wild-Type Healthy Animals

The first *CTSB* KO mouse article reported that the *CTSB* KO mice (generated in the 129 strain and later backcrossed for more than 10 generations to C57BL/6) appeared normal and had the same major histocompatibility complex class II-mediated antigen presentation as wild-type mice (Deussing et al., 1997). *CTSB* KO mice were reported to be healthy and indistinguishable from heterozygous and wild-type littermates, based on histologic inspection of external and internal organs, which showed normal tissues in the brain, heart, lung, liver, spleen, thyroid, pancreas, stomach, intestine, ovary, kidney, skeletal muscle, and lymph nodes in the *CTSB* KO animals (Halangk et al., 2000; Reinheckel et al., 2001). Moreover, those studies reported that *CTSB* KO mice were fertile, reproduce normally, and had no abnormalities in T or B lymphocytes. Thus, deletion of the *CTSB* gene results in animals that are healthy and similar to wild-type mice.

While *CTSB* KO mice are generally phenotypically indistinguishable from wild-type mice, several biochemical differences have been considered. For example, *CTSB* KO animals display higher levels of thyroid prohormone thyroglobulin relative to wild-type animals. Nonetheless, *CTSB* KO mice maintain normal

blood thyroid hormone thyroxine levels and thus do not display hyperthyroid pathology (Friedrichs et al., 2003). Analysis of the *CTSB* KO mouse skin proteome determined that nine proteins in the ubiquitin proteasome and vascular endothelial growth factor signaling pathways are more abundantly expressed compared with wild-type mice, and six proteins in the serine protease inhibitor class are less abundantly expressed relative to wild-type mice (Tholen et al., 2013). But such differences do not phenotypically affect *CTSB* KO animals since they have normal skin and fur.

*CTSB* KO mice exhibit several subtle behavioral differences compared with wild-type mice. For example, female *CTSB* KO mice display slightly higher anxiety than female wild-type mice as measured in a swim test (Czibere et al., 2011). In another study, running improves memory and increases hippocampal neuronal cell density in wild-type mice compared with sedentary animals, but in *CTSB* KO mice these effects of running were not observed (Moon et al., 2016). But, as described in this review article (next section VIII), eliminating *CTSB* gene expression generally improves memory and pathology in animal models of brain disorders. Thus, eliminating *CTSB* appears to cause different effects in normal versus neurologic disease models.

*CTSB* functions in concert with other lysosomal proteases, most importantly with the other cysteine type cathepsins of which a total of 11 proteases that share considerable homology are encoded in the human genome (Ketterer et al., 2017). In mice, the *CTSB* gene has been simultaneously deleted with the cathepsin S or cathepsin Z gene and even a triple KO of the three proteases has been generated. Interestingly, mice with those gene KO combinations, like single *CTSB* KO mice, are viable, healthy, and reproduce normally. (Sevenich et al., 2010; Allan and Yates 2015; Akkari et al., 2016).

However, double deficiency of *CTSB* and cathepsin L genes is lethal a few weeks after birth due to neurodegeneration resembling human ceroid-lipofuscinoses (Felbor et al., 2002; Koike et al., 2005). This lethal phenotype can be rescued by expression of human cathepsin L in *CTSB*/cathepsin L double deficient mice, indicating reciprocal functional compensation between the two enzymes (Sevenich et al., 2006).

Generally, the *CTSB* KO mice are healthy, indicating physiologic functions that are operational. These findings suggest that inhibition of *CTSB* by chemical molecules as candidate drug agents will generally display a healthy phenotype.

### VIII. Cathepsin B Knockout Improves Behavioral Deficits in Neurologic Disease Animal Models

Numerous neurologic animal model conditions are improved by knockout of the *CTSB* gene. *CTSB* deletion

ameliorates behavioral deficits, neuropathology, and biomarkers in numerous brain disorders including traumatic brain injury, ischemia, epilepsy, multiple sclerosis, opioid tolerance, and inflammatory pain (Table 3), assessed in this section.

#### A. Cathepsin B in Neuromotor Dysfunction, Brain Tissue Loss, and Hippocampal Cell Death in Traumatic Brain Injury

TBI occurs when external forces to the brain result in a range of injuries of mild to severe injuries, closed and open head injuries, and nonpenetrating or penetrating injuries (reviewed in Saatman et al., 2008; Dixon, 2017). These injuries lead to severe brain dysfunction, tissue damage, and neurodegeneration, resulting in death and severe disability among all ages (Faul et al., 2010). TBI is suffered by over 10 million people per year worldwide (reviewed in Hyder et al., 2007).

In the CCI model of TBI, *CTSB* gene expression in the brain is increased (Natale et al., 2003), and *CTSB* activity and enzyme protein levels are increased in the brain (Luo et al., 2010; Hook et al., 2014a). In the penetrating ballistic-like brain injury animal model of TBI, substantial increases in *CTSB* activity and enzyme levels occur at 1, 3, and 7 days after the injury (Boutte et al., 2020).

The role of *CTSB* in mediating the behavioral deficits and neuropathology of CCI-TBI has been demonstrated by *CTSB* KO studies (Hook et al., 2014a). *CTSB* KO eliminated the CCI-induced increases in *CTSB* and resulted in improved neuromotor dysfunction at 1 day and 7 days postinjury, amelioration of brain tissue loss at 7 days post-CCI, and reduced hippocampal cell death in CCI-TBI at 7 days post-CCI (Hook et al., 2014a). Furthermore, *CTSB* KO blocked the CCI-induced rise in Bax, a proapoptotic cell death protein. The paper concluded that “These results validate cathepsin B as a new TBI therapeutic target” (Hook et al., 2014a, page 515,” Abstract,” last sentence).

In TBI, *CTSB* has been found to undergo lysosomal leakage translocation to the cytosol in brain neurons during increased intracranial pressure (ICP) in a moderate TBI rat model (Lafrenaye et al., 2012). Brain neurons in these TBI animals displayed chronic membrane poration in the elevated ICP condition compared with animals with only transient ICP. In fact, neuronal membrane disruption occurs acutely after injury and continues with a biphasic time-dependent elevation during 6 hours to 3 days post-TBI and 2 to 4 weeks after TBI in subsets of neurons in the central fluid percussion injury TBI model in rats (Hernandez et al., 2019).

The *CTSB* KO results suggest that chemical inhibition of *CTSB* will have beneficial effects for TBI. Indeed, chemical inhibition of *CTSB* and cathepsins by E64c improved motor dysfunction and ameliorated

brain tissue and neuronal loss in CCI-TBI mice (Hook et al., 2014a). The chemical molecule (+)-(2S,3S)-3-(1-[N-(3-methylbutyl)amino]-leucylcarbonyl) oxirane-2-carboxylic acid, known as E64c, is a potent pan cysteine cathepsin inhibitor (Tamai et al., 1986), which is administered (oral) as a prodrug form, E64d (EST, Aloxistatin, *L-trans*-epoxysuccinyl(OEt)-Leu3methylbutamide). E64d treatment reduced neuromotor disability, reduced brain tissue loss, and decreased neuronal cell loss in the CCI mice.

Furthermore, reduction of CTSB activity with the cathepsin B inhibitor, CA-074, also improved CCI-induced motor and cognitive deficits with reduced neurodegeneration in this TBI model (Luo et al., 2010). The inhibitor attenuated TBI-induced cell death, lesion volume, and motor and cognitive dysfunction.

CTSB studies have demonstrated the prominent role of CTSB in mediating TBI-induced brain deficits (Luo et al., 2010; Hook et al., 2014a; Boutte et al., 2020). It is realized that TBI injuries are diverse, and it will, therefore, be advantageous to investigate the role of CTSB in multiple TBI models.

### *B. Cathepsin B in Hippocampal Cell Death and Neuroinflammation in Hypoxia/Ischemia*

Hypoxic-ischemic (HI) brain injury, caused by deficient oxygen supply, is a leading cause of death and severe disability. The high metabolic rate of the brain is compromised in hypoxic-ischemia such that ATP energy demands cannot be met, which results in dysfunctional neurons, synaptic dysfunction, and cell death. Notably, in human neonates, HI is the most common cause of death and disability, and occurs as a result of asphyxia of the umbilical blood supply to the fetus (reviewed in du Plessis and Volpe, 2002). Among those who survive, high rates of disability occur, including cognitive impairment, neuromotor dysfunction, and seizures.

In a neonatal HI model, *CTSB* gene KO resulted in substantial improvements in outcomes shown by reductions in neuronal cell death and neuroinflammation involving neurotoxic M1 microglia (Ni et al., 2015). HI increased CTSB and activated the neurotoxic M1 microglia type (Hu et al., 2012; Orihuela et al., 2016), which displayed elevated inducible nitric oxide synthetase, TNF- $\alpha$ , and IL-1 $\beta$  mRNA levels by 200-, 8-, and 50-fold, respectively, above noninjured controls. These data show that *CTSB* KO blocked the HI-induced neurotoxic M1 phenotype in HI mice. *CTSB* KO also resulted in enhancement of the neuroprotective M2 phenotype of microglia with anti-inflammatory IL-4 and IL-10. Furthermore, the aspartic protease cathepsin E was found as an upstream regulator of increased CTSB, which activates nuclear factor  $\kappa$ B (NF- $\kappa$ B) to polarize microglia into a neurotoxic phenotype and increase CTSB (Ni et al., 2015).

*In vitro* cell studies then assessed mechanisms of CTSB activation of microglial in HI, by subjecting cells to oxygen-glucose deprivation followed by reoxygenation (Ni et al., 2015). Oxygen-glucose deprivation of microglial cells initiated autophagy, increased CTSB levels, and increased NF- $\kappa$ B. The CTSB inhibitor CA-074Me prevented the activation of NF- $\kappa$ B by inhibiting degradation of its inhibitor of NF- $\kappa$ B during oxygen-glucose deprivation of microglia cells. These findings suggest that CTSB activated NF- $\kappa$ B to promote the neurotoxic M1 phenotype. NF- $\kappa$ B is a master gene regulator that is activated by diverse stimuli, including oxidative stress, and is a three-component system consisting of NF- $\kappa$ B, inhibitor of NF- $\kappa$ B, and I $\kappa$ B kinase complex (Ghosh et al., 2012). When activated, NF- $\kappa$ B translocates from the cytoplasm to the nucleus where it activates genes that control inflammation, cell death, and other functions controlled by phosphorylation of NF- $\kappa$ B subunits (Christian et al., 2016).

Overall, these studies of *CTSB* KO in the neonatal HI mouse model provide strong evidence for involvement of CTSB, regulated by upstream cathepsin E, in HI-induced neuronal death (Ni et al., 2015). The paper concluded that “inhibitors of cathepsin B or E as promising pharmacological agents for the treatment of ischemic brain injury” (Ni et al., 2015, page 12488, “Significance Statement,” last line).

### *C. Cathepsin B in Brain Neuronal Cell Death in Epilepsy*

Progressive myoclonic epilepsy of the Unverricht-Lundborg (EPM1) is a rare genetically inherited autosomal recessive form of epilepsy that develops in childhood, resulting in lighting-like myoclonic jerks and tonic-clonic seizure attacks, and causes mental retardation and severe ataxia (reviewed in Kälviäinen et al., 2008). Notably, knockout of the *CTSB* gene in a EPM1 neuropathological model resulted in decreased neuronal apoptotic cell death in the brain, indicating that CTSB contributes to cell apoptosis in EPM1 (Pennacchio et al., 1996; Houseweart et al., 2003). This was one of the first studies to evaluate *CTSB* KO in a neurologic disease model.

EPM1 is a genetic disease caused by loss of function mutations in the cystatin B gene, an endogenous inhibitor of CTSB and cysteine cathepsins (Pennacchio et al., 1996). The cystatin B KO mice were used as an EPM1 model having seizures and loss of cerebellar granule neurons (Pennacchio et al., 1998; Houseweart et al., 2003). The absence of cystatin B in EPM1 leads to elevated cysteine cathepsin activity, which induces apoptotic cell death. To assess the roles of the cysteine cathepsins CTSB, cathepsin L, or cathepsin S in the EPM1 phenotypes, knockout of each of these cathepsin genes was conducted (Houseweart et al., 2003). Knockout of *CTSB*, but not of

cathepsin L or cathepsin S, reduced apoptosis in the EPM1 mice, but had no effect on seizures. These findings suggest a role for CTSB in cell death of EPM1, and other mechanisms participating in EPM1 seizures.

Further evidence for a role of CTSB in cell death was provided by studies of overexpression of the *CTSB* gene in the cystatin B KO EPM1 model (Houseweart et al., 2003). In heterozygote *CTSB* and cystatin B KO EPM1 mice, increased apoptosis was observed, but the low number of heterozygote mice precluded statistical analyses. Further, the low birth number of transgenic *CTSB* and cystatin B KO mice showed that *CTSB* expression and eliminating its endogenous inhibitor, cystatin B, was a lethal combination. The authors concluded that “these findings establish cathepsin B as a contributor to apoptotic phenotype of cystatin B-deficient mice and humans with EPM1” (Houseweart et al., 2003, page 315, “Abstract,” second to last sentence).

#### D. Cathepsin B and Cathepsin S in Multiple Sclerosis

MS is a complex inflammatory CNS disease resulting in the destruction of the insulating myelin surrounding neuronal axons, which results in neurologic impairments, inflammation, and lesions (reviewed in Correale et al., 2017). The disease is driven by an autoimmune reaction of CNS-infiltrating myelin-specific autoreactive lymphocytes. Widespread activation of macrophages and microglia in the CNS occurs along with extensive immune infiltration of reactive lymphocytes and macrophages. A commonly used model of MS is the experimental autoimmune encephalomyelitis (EAE) model in which myelin oligodendrocyte glycoprotein antigen in Freund’s adjuvant and pertussis toxin are administered (subcutaneous and intraperitoneal routes) to animals to drive activation of CD4+ T lymphocytes in an autoimmune response mimicking MS (Nakahara et al., 2010).

Lysosomal cysteine cathepsins, including CTSB, are highly expressed in antigen presenting cells and are critical for processing antigens and the major histocompatibility-class II invariant chain in autoimmune conditions. Cathepsin S has also been thought to play an important role in MS because a cathepsin S inhibitor, a peptide containing the amino acids leucine-histidine-valine-serine (LHVS), affected antigen presentation (Riese et al., 1998) and attenuated EAE in wild-type mice (Fissolo et al., 2008). But since LHVS is a broad spectrum cysteine protease inhibitor (Wilson et al., 2009), only gene KO studies can assess the specific role of cathepsin S.

Evaluation of *CTSB* KO and cathepsin S KO mice in the EAE model (Allan and Yates, 2015) showed that CTSB and cathepsin S represent dual targets for a candidate MS therapeutic approach. Double cathepsin S and *CTSB* KO in EAE mice resulted in

improvements consisting of 40% reduction in major histocompatibility-class II invariant chain expression, 82% reduction in CD4+ cells presenting CD69 antigen challenged with small myelin oligodendrocyte glycoprotein antigen peptides, 82% improvement in clinical score, 21% increase in the time of onset, and approximately 100% fewer infiltrating leukocytes macrophages, CD4+ T cells, and CD8+ T cells in spinal cord and about 75% lower for microglia relative to wild-type EAE animals. However, EAE animals with *CTSB* KO or cathepsin S KO each displayed similar EAE phenotypes as wild-type EAE mice. Thus, inhibition of both CTSB and cathepsin S represents a new poly target therapeutic approach for MS that is yet to be exploited. The authors concluded that cathepsin B and S are redundant in the EAE model and that “inhibition of multiple cysteine cathepsins may be needed to modulate autoimmune disorders, such as multiple sclerosis” (Allan and Yates, 2015, page 1, “Abstract,” last sentence).

#### E. Cathepsin B in Inflammatory Pain

Chronic pain is a detrimental condition that causes widespread disability in the world. Chronic pain is not merely a symptom of a disease or condition but rather a distinct condition that can result from inflammatory diseases (inflammatory pain) or nerve injury (neuropathic pain). Chronic pain contrasts with normal pain sensitivity that is essential for avoiding dangerous conditions.

CTSB participates in inflammatory pain as demonstrated in studies of *CTSB* KO mice (Sun et al., 2012). *CTSB* deficiency inhibited the induction of tactile allodynia induced by complete Freund’s adjuvant (CFA) in mice, without affecting peripheral inflammation. But *CTSB* KO did not affect nerve injury-induced allodynia for neuropathic pain, indicating the selective role of CTSB in inflammatory pain. In inflammatory pain, *CTSB* KO inhibited CFA induction of spinal IL-1 $\beta$ , IL-18, and cyclooxygenase-2. *CTSB* KO also reduced CFA-induced increases in spinal microglia cell size. These data indicate that CTSB participates in the development of chronic inflammatory pain through maturation of IL-1 $\beta$  and IL-18 by spinal microglia. These findings support the strategy of using inhibitors of CTSB to selectively treat inflammatory pain, but not nerve injury-induced neuropathic pain.

Inflammatory and neuropathic pain cause microglial activation to the neurotoxic M1 phenotype for production of inflammatory cytokines (Carniglia et al., 2017; Zhao et al., 2017). A key difference between the two forms of pain is that different proteases participate in production of inflammatory cytokines. In inflammatory pain, lysosomal CTSB leaks into the cytosol where the enzyme activates the NLRP3 inflammasome and caspase-1 (Halle et al.,

2008; reviewed in Tschopp and Schroder, 2010). However, in neuropathic pain, metalloproteases participate in the process to activate caspase-1 (Kawasaki et al., 2008). The caspase-1 enzyme is necessary for cleavage of procytokines to generate the proinflammatory cytokines IL-1 $\beta$  and IL-18 (Martinon et al., 2002). Subsequent to cytokine production, the molecular pathways to pain diverge in these two pain conditions. In inflammatory pain, IL-1 $\beta$  causes an increase in COX-2 and prostaglandin E<sub>2</sub> in the spinal cord that contributes to pain hypersensitivity (Samad et al., 2001; Ren and Torres, 2009). In neuropathic pain, IL-1 $\beta$  does not affect spinal COX-2 and activates other molecular pain mechanisms (Sweitzer et al., 2001; Broom et al., 2004).

Based on the evidence for a significant role of CTSB in inflammatory pain, the authors concluded that CTSB is essential for activation of IL-1 $\beta$  in inflammatory, but not neuropathic, pain and that “CTSB-specific inhibitors may represent a useful new strategy for treating inflammation-associated pain” (Sun et al., 2012, page 11341, right column, last sentence).

#### *F. Cathepsin B in Tolerance with Chronic Opioid Use*

Opiates are the most effective therapeutic agent for controlling severe pain, but long-term use results in the problem of antinociceptive tolerance in which opioids lose their analgesic efficacy, requiring dose escalation for pain relief (reviewed in Martyn et al., 2019). Importantly, CTSB participates as a mechanism by which chronic morphine causes antinociceptive tolerance through activation of autophagy involving increased neuroexcitatory transmitter release (Zhao et al., 2010). Significantly, deletion of the *CTSB* gene prevents tolerance to chronic morphine assessed by allodynia of the von Frey test (Hayashi et al., 2014). These CTSB knockout studies show that opiate tolerance is dependent on CTSB.

*CTSB* KO mice do not develop chronic morphine-induced increases in autophagy, and *CTSB* KO inhibited glutamate neurotransmitter release during chronic morphine (Hayashi et al., 2014). Whereas wild-type mice exhibit increased glutamate release in lamina I neurons with chronic morphine treatment, *CTSB* KO mice do not exhibit such changes in glutamate during chronic morphine. These findings indicate that chronic morphine causes excessive CTSB-dependent autophagy in GABAergic neurons, which causes dysregulation and a reduction of GABAergic neuronal inhibition that increases excitatory glutamate release.

The authors of the *CTSB* KO studies in chronic morphine concluded that “[CTSB] inhibitors can be beneficial in the blockade of opioid antinociceptive tolerance” (Hayashi et al., 2014, page 392, “Conclusion,” last sentence).

#### *G. Cathepsin B in Memory Deficits in Aging*

Aging is a main risk factor in neurodegenerative diseases and neurologic conditions that involve CTSB mediation of neuroinflammation and memory impairment (Terada et al., 2010; Stoka et al., 2016; Ni et al., 2019). Significantly, knockout of the *CTSB* gene reduced inflammation and improved cognitive impairment in aged mice but not in young mice (Ni et al., 2019). These studies showed that aging hippocampal microglia display increases in CTSB combined with lysosomal leakage of CTSB that mediates generation of mitochondria-derived reactive oxygen species (ROS) and activation of proinflammatory IL-1 $\beta$  and TNF- $\alpha$  (Ni et al., 2019). Knockout of *CTSB* attenuated elevation of ROS and inflammation in aging. Importantly, knockout of *CTSB* resulted in significant improvement of memory deficits in aged mice. These findings demonstrate that CTSB participates in activation of innate immunity related to cognition during aging.

The relationship of lysosomal leakage of CTSB and ROS production was assessed in microglia cell cultures (Ni et al., 2019). Induction of lysosomal leakage by L-leucyl-L-leucine methyl ester, a lysosome destabilizing agent, resulted in CTSB-dependent increases in cellular ROS generation and inflammatory responses in microglia. Furthermore, induction of oxidative stress and inflammation with rotenone treatment of microglia cells was blocked by an inhibitor of CTSB, CA-074Me. Leaked CTSB participated in degradation of cytosolic pre-TFAM, a potential substrate of CTSB that functions as a mitochondrial transcription factor and stabilizer of mitochondria. The same research group also found increased nuclear location of CTSB in microglia with aging; nuclear CTSB was involved in the degradation in sirtuins and activation of NF $\kappa$ B (Meng et al., 2020). Notably, impairment of learning and memory occurred in aged mice after injection of L-leucyl-L-leucine methyl ester-treated CTSB-overexpressing microglia cells into the lateral ventricle of the brain, but not by untreated CTSB-expressing microglia. These findings indicate that increased CTSB participates in activation of mitochondria-derived ROS and proinflammatory mediators that result in memory impairment in aging (Ni et al., 2019; Meng et al., 2020).

Overall, the CTSB dependence of memory deficits in aged mice, shown by *CTSB* KO studies, led the authors to conclude that “the increase and leakage [from lysosomes] of CTSB in microglia during aging are responsible for the increased generation of mitochondria-derived ROS and proinflammatory mediators, culminating in memory impairment” (Ni et al., 2019, Abstract, last sentence).

The endogenous chromogranin A (CgA) peptide neurotransmitter (neuropeptide) participates in lysosomal leakage of CTSB, with elevation of CTSB enzyme



levels, leading to activation of IL-1 $\beta$  production (Terada et al., 2010). Studies of primary microglia cells from *CTSB* KO and wild-type mice brain cortex (in culture) showed that *CTSB* gene deletion prevented CgA induction of IL-1 $\beta$  secretion and also reduced CgA activation of cell death. *CTSB* KO attenuated *CTSB* processing of pro-caspase 1 to active caspase 1 that cleaves pro-IL-1 $\beta$  to generate IL-1 $\beta$ . These findings demonstrate participation of lysosomal *CTSB* in production of IL-1 $\beta$  in CgA-activated microglia cells that accumulate neuroinflammation in Alzheimer's disease, Parkinson's disease, and Pick neurodegenerative disease conditions in aging (Weiler et al., 1990; Brion et al., 1991; Yasuhara et al., 1994). Based on these findings, authors concluded that "either pharmacological or genetic inhibition of [*CTSB*] may provide therapeutic intervention in inflammation-associated neurological diseases" (Terada et al., 2010, page 114, "Abstract," last line).

#### *H. Cathepsin B in Memory Deficits, Neuroinflammation, and Amyloid- $\beta$ in Chronic Periodontitis-Associated Alzheimer's Disease*

AD results in severe memory loss (reviewed in Masters et al., 2015; Lane et al., 2018) and neuroinflammation (reviewed in Akiyama et al., 2000; Heneka et al., 2015; Ardura-Fabregat et al., 2017). Infectious AD etiology by *Porphyromonas gingivalis*, the major periodontal bacteria, and numerous chronic viral, fungal, and bacterial infections have been shown to participate in AD (reviewed in Sochocka et al., 2017). Strong clinical evidence indicates a positive link between periodontitis and AD with respect to cognitive dysfunction and inflammation (reviewed in Singhrao et al., 2015; Teixeira et al., 2017), supported by the presence of *Porphyromonas gingivalis* lipopolysaccharide (PgLPS) in the human AD brain (Poole et al., 2013). Significantly, *CTSB* has been found to participate in PgLPS-induced periodontitis and memory deficits (Wu et al., 2017).

*CTSB* KO studies in the neuroinflammatory periodontitis model of AD demonstrated that *CTSB* drives memory deficits through activation of microglia inflammation and neuronal amyloid-beta ( $A\beta$ ) production (Wu et al., 2017). Knockout of *CTSB* in the PgLPS mice significantly improved memory deficits in middle-aged mice (12 months old), but not in young mice (2 months), treated with PgLPS for 5 weeks (i.p., 1 mg/kg daily). PgLPS elevated *CTSB* in hippocampus and this elevated *CTSB* was absent in *CTSB* KO mice treated with PgLPS. Further, *CTSB* KO reduced inflammatory responses, indicated by reductions IL-1 $\beta$  and toll-like receptor 2 in microglia. These effects of *CTSB* KO for improving memory deficits and reducing inflammation occurred in middle-aged mice, but not in young mice, treated with PgLPS. The amelioration by *CTSB* KO of PgLPS induced memory loss and neuroinflammation support *CTSB* as a candidate drug target for

discovery of therapeutic agents for cognitive decline in chronic periodontitis-associated AD (Wu et al., 2017).

*CTSB* KO blocks PgLPS-induced elevation of  $A\beta(1-42)$  in the mouse brain (Wu et al., 2017), indicating that  $A\beta(1-42)$  production is dependent on *CTSB*. In cellular studies, PgLPS induces release of IL-1 $\beta$  from microglia cells, and incubation of the resultant microglia IL-1 $\beta$ -containing conditioned medium with neurons resulted in increased *CTSB*, APP, and  $A\beta$ . IL-1 $\beta$  regulation of neurons may involve *CTSB* activation of NF- $\kappa$ B that drives expression of APP and *CTSB*, shown to function as an alternative  $\beta$ -secretase for  $A\beta$  production (Hook et al., 2005, 2008b). These results show that *CTSB* participates in  $A\beta$  production for amyloidosis of periodontitis related to AD.

The role of *CTSB* in elevation of  $A\beta$  in chronic periodontitis (Wu et al., 2017) has been corroborated by several studies (Rong et al., 2020). PgLPS increases *CTSB* and elevates  $A\beta(1-40)$  and  $A\beta(1-42)$  in neuroblastoma cells expressing wild-type human APP, but had no effect on APP or beta-site amyloid precursor protein cleaving enzyme (BACE) 1 levels. The *CTSB* inhibitor CA-074Me blocked PgLPS-induced increases in  $A\beta(1-40)$  and  $A\beta(1-42)$ , indicating involvement of *CTSB* in  $A\beta$  peptide production. Clinical data show that serum *CTSB* levels are significantly elevated in patients with chronic periodontitis, and higher serum *CTSB* levels correlate with cognitive deficits in periodontitis patients. These findings support involvement of *CTSB* in  $A\beta$  production and memory deficits in chronic periodontitis related to AD (Rong et al., 2020).

*CTSB*-dependent increases in  $A\beta$  have been reported in advanced glycation end (AGE) products, another model of neurodegeneration (Batkulwar et al., 2018). AGE results from a nonenzymatic reaction of glucose or other glycolytic intermediates with proteins to induce toxic neuronal effects through the AGE receptor involved in neurodegeneration. AGE treatment of mouse neuro2a or cortical neurons increased *CTSB* and  $A\beta(1-42)$ , which was reduced by CA-074Me inhibition of *CTSB*. Also, *CTSB* is elevated in human brain cortex of patients with AD compared with age-matched controls. These findings suggest that cathepsin B may have a role in AGE-RAGE [receptor for AGE (RAGE)] signaling that exacerbates the onset and development of  $A\beta(1-42)$  pathology of AD (Batkulwar et al., 2018).

Additional support for *CTSB*-dependent processing of wild-type APP has been provided in studies of a mouse model of mucopolysaccharidosis type I (MPS I). MPS I is a rare disease resulting in neurologic deficits, caused by a genetic deficiency of  $\alpha$ -L-iduronidase (IDUA) involving an impairment of lysosomal catabolism, which is modeled by knockout of the IDUA gene in mice (Viana et al., 2020). This MPS 1 model

displayed elevated CTSB, activation of microglia and astrocytes, and elevated APP  $\beta$ -secretase processing, and no effect on BACE1 levels. CTSB was significantly increased in the cytoplasm of hippocampal pyramidal neurons from IDUA KO mice, indicating lysosomal leakage of CTSB. The study concluded that CTSB represents an alternative amyloidogenic pathway in MPS I brain involving lysosomal leakage of CTSB that may lead to neurodegeneration (Viana et al., 2020).

CTSB regulation of A $\beta$  production from multiple neurodegenerative disease models of periodontitis, AGE, and MPS I that express WT APP are relevant to patients with sporadic AD expressing normal WT APP, representing the majority (>95%) of the AD population. A small percentage of FAD, involving AD genetic mutations, comprise less than 5% of AD cases (Price and Sisodia, 1998; Van Cauwenberghhe et al., 2016). Since most patients with AD are sporadic (~95%), the role of CTSB in A $\beta$  production from WT APP is relevant for the major portion of the population with AD.

Evidence supports CTSB as an alternative  $\beta$ -secretase used for conversion of APP, together with  $\gamma$ -secretion, into A $\beta$  peptides (Hook et al., 2008a, 2008b, 2009, 2014b; Kindy et al., 2012; Wu et al., 2017). Although BACE1 has been viewed as the only  $\beta$ -secretase (Laird et al., 2005; Willem et al., 2009; Hampel et al., 2021), based in part on findings that BACE1 KO mice had no  $\beta$ -secretase activity (Roberds et al., 2001), the data do not rule out CTSB since the assay included an inhibitor of CTSB and lacked reducing conditions necessary for CTSB activity. It is noteworthy that APP  $\beta$ -secretase processing involves several proteases in addition to BACE1 (reviewed by Vassar, 2004; Andrew et al., 2016; Hasanbasic et al., 2016), which include CTSB (Hook et al., 2008b; Terada et al., 2010; Wu et al., 2017; Batkulwar et al., 2018; Ni et al., 2019; Rong et al., 2020; Viana et al., 2020), delta-secretase (Zhang et al., 2015; Wu et al., 2020), meprin (Becker-Pauly and Pietrzik, 2017; Schlenzig et al., 2018), and matrix metalloproteinases (Garcia-Gonzalez et al., 2019).

Overall, evidence for involvement of CTSB in A $\beta$  production and memory deficits in chronic periodontitis related to AD have led authors to conclude that “CTSB might be the link between chronic periodontitis and AD” (Rong et al., 2020, page 9, last paragraph, second sentence).

### *I. Cathepsin B in Memory Deficits and Amyloid- $\beta$ in Transgenic Human Amyloid Precursor Alzheimer's Disease Models*

CTSB KO studies have been conducted in transgenic AD mouse models overexpressing human amyloid precursor protein (hAPP) by two groups, Hook (Hook et al., 2009; Kindy et al., 2012; Hook et al., 2014b) and Gan (Mueller-Steiner et al., 2006; Wang et al., 2012). These models produce human A $\beta$ , and some develop brain A $\beta$  plaque and memory impairment. Six different transgenic CTSB KO and hAPP AD mouse models

were studied (summarized in Table 4). The two groups obtained confirming and conflicting data, with the latter being likely due to differences in the hAPP transgene used.

1. *Transgenic Human Amyloid Precursor Protein Used in Cathepsin B Knockout Alzheimer's Disease Models Differ in the  $\beta$ -Secretase Site Sequence, Amyloid Precursor Protein Isoform, and Gene Construct.* Transgenic AD models used to evaluate CTSB differed in three significant aspects consisting of the hAPP amino acid sequence at the  $\beta$ -secretase cleavage site, the hAPP isoform expressed, and the genetic engineering construct of the hAPP. The models expressed hAPP with either the WT  $\beta$ -secretase site found in the vast majority of patients with AD or the familial Swedish mutation of amyloid precursor protein (Swe) mutant  $\beta$ -secretase site sequence (K670N/M671L) found in one extended family (Mullan et al., 1992). This difference has a major effect on CTSB ability to cleave that site as it readily cleaves the WT but does not cleave the Swe  $\beta$ -secretase site sequence (Hook et al., 2008a). Both groups used both types of hAPP models, and, as discussed below, the Hook group found that CTSB gene deletion caused a major reduction in  $\beta$ -secretase cleavage products, including A $\beta$ , brain plaque, and memory deficits in models expressing hAPP with WT  $\beta$ -secretase site sequence but had no effect in models expressing the Swe mutant  $\beta$ -secretase site sequence (Table 4). The Gan group found that CTSB KO had no effect on A $\beta$  production and a slight brain A $\beta$  degradation effect in a model expressing hAPP with WT  $\beta$ -secretase site sequence (Table 4). In a model expressing Swe mutant  $\beta$ -secretase site sequence, the Gan group confirmed the Hook group's finding that CTSB had no effect on A $\beta$  production but had a degradative effect on brain plaque.

The hAPPs used by the two groups differed in isoforms of hAPP that were expressed. The Hook group studied the hAPP 695 isoform expressed in AD mice, whereas the Gan group used the hAPP 751/770 isoform in mouse studies. The hAPP is expressed as isoforms containing either 770, 695, or 751 amino acids. hAPP-695 is the most abundant, is exclusively expressed in neurons, and is processed into A $\beta$  (Fig. 4Ai) (Sandbrink et al., 1993; Rockenstein et al., 1995; Rohan de Silva et al., 1997). APP-751 and APP-770 isoforms are present at much lower levels (Tanaka et al., 1989; Kang and Müller-Hill, 1990; Jacobsen et al., 1991; Rockenstein et al., 1995; Rohan de Silva et al., 1997), which are expressed primarily in glia cells and generate nonamyloidogenic sAPP $\alpha$  (Fig. 4Bi). (Kametani et al., 1993; Nalivaeva and Turner, 2013). With respect to trafficking, APP695 forms *cis*-dimers within the endoplasmic reticulum of cells, whereas APP-751/770 prevents that from occurring and APP-751/770 is present only as *trans*-dimers (Isbert et al.,

TABLE 4  
 Cathepsin B Gene Knockout Improves Memory Deficits in AD and Aging Models

Animal Model	hAPP Isotype			CTSB Knockout Improves Memory Deficits and Outcomes in hAPP AD Models			References
	Isotype, Cell Type	$\beta$ -Secretase Site	$\gamma$ -Secretase Site	Memory Deficits	Cellular and Biomarker Features	Pathology	
Aging	Mouse APP isoforms of 695 in neurons and isoforms 751 and 770 in glia	WT	WT	↓Memory deficits	↓Activated macrophages, ↓inflammatory cytokines, ↓oxidative stress, ↑long-term potentiation	nd	Terada et al., 2010; Ni et al., 2019
Periodontitis AD	Mouse APP isoforms of 695 in neurons and 751 and 770 in glia	WT	WT	↓Memory deficits	↓Activated macrophages ↓A $\beta$ (1-42), ↓inflammatory cytokines	nd	Wu et al., 2017
AD	hAPP-WT-695, neuronal expression (PDGF promoter)	WT	WT	n/a	↓A $\beta$ (1-42) by ~70% ↓ $\beta$ (1-40) by ~70% ↓CTF $\beta$ by 40%, ↑sAPP $\alpha$ by 60%, ↓WT $\beta$ -secretase activity	n/a	Hook et al., 2009
AD	hAPP-WT-Lon-695, neuronal expression (PDGF promoter)	WT	Lon, V717I	↓Memory deficits	↓A $\beta$ (1-40) by 85% ↓A $\beta$ (1-42) by 87% ↓pGluA $\beta$ (3-40) by 65% ↓pGluA $\beta$ (3-42) by 92% ↓CTF $\beta$ by 60% ↑sA $\beta$ PP $\alpha$ by 60% ↓WT $\beta$ -secretase activity	↓A $\beta$ plaque by 85%, ↓pGluA $\beta$ plaque by 46%	Kindy et al., 2012; Hook et al., 2014b
AD	hAPP-Swe-Lon-695, neuronal expression (PDGF promoter)	Swe, K670N/M671L	Lon, V717I	No effect on memory deficits	No effects on A $\beta$ (1-42), CTF $\beta$ , or APP $\alpha$	No effect on amyloid plaque	Kindy et al., 2012
AD	hAPP-Swe-Ind-695, neuronal expression (PDGF promoter)	Swe K670N/M671L	Ind, V717F	n/a	No effects on A $\beta$ , CTF $\beta$ , or sAPP $\alpha$	n/a	Hook et al., 2009

(continued)

TABLE 4—Continued  
CTSB Knockout Improves Memory Deficits and Outcomes in hAPP AD Models

Animal Model	hAPP Isozyme	$\beta$ -Secretase Site	$\gamma$ -Secretase Site	Memory Deficits	Cellular and Biomarker Features	Pathology	References
AD	hAPP-Swe-Ind-751/770, neuronal expression (PDGF promoter), J20 line, introns modified, PDAPP	Swe	Ind	nd	No change in hAPP, $\beta$ -CTF, $\alpha$ -sAPP, or $\alpha$ -CTF $\uparrow$ A $\beta$ (1–42)/A $\beta$ (1–x) ratio by ~25%	Elevated plaque load	Mueller-Steiner et al., 2006
AD	hAPP-751/770, neuronal expression (PDGF promoter, I63 line, introns modified, PDAPP)	WT	WT	nd	No change in hippocampal A $\beta$ 42, $\downarrow$ cortical A $\beta$ 42 by 12%	nd	Wang et al., 2012

nd, not determined; n/a, not applicable.


2012). As a result, APP-695 is preferentially trafficked through the amyloidogenic endosomal pathway in lipid rafts (Cordy et al., 2003; Eehalt et al., 2003). In contrast, APP-751/770 has been found to undergo trafficking and processing by the nonamyloidogenic cell-surface pathway (Cordy et al., 2003; Eehalt et al., 2003; Ben Khalifa et al., 2012; Nalivaeva and Turner, 2013). The Hook group used models expressing hAPP-695, whereas the Gan group used models expressing hAPP-751/770. As discussed below, the difference in isoform may have caused different *CTSB* KO outcomes found by the two groups.

The hAPP genetic engineered construct differed between the two groups. The Hook group used the naturally occurring hAPP-695 gene sequence, whereas the Gan group used a highly modified hAPP-751/770 gene in which introns were deleted and nucleic acid base-pairs added (Rockenstein et al., 1995). Both groups used the platelet derived growth factor (PDGF) promoter in the transgene to induce hAPP expression in neurons and not in other brain cells (Sasahara et al., 1991). This resulted in the hAPP-695 used by the Hook group being expressed in neurons that naturally occur (Fig. 4Aii). However, the PDGF promoter forced the hAPP-751/770 used by the Gan group to be expressed in neurons where those isoforms are not naturally produced (Fig. 4Bii), which contrasts with the normal glia expression of hAPP-751/770 (Fig. 4Bi). Thus, the genetic engineering differences may contribute to the differences in results obtained by the two groups.

*2. Major Cathepsin B Dependency of Memory Deficits and Amyloid- $\beta$  in Human Amyloid Precursor Protein with Wild-Type  $\beta$ -Secretase Site Sequence and Amyloid Precursor Protein Isoform 695 Alzheimer's Disease Models, Representative of Most Alzheimer's Disease Patients.* The transgenic WT hAPP-695 (no mutations) model most closely mimics the hAPP processing that occurs in the neurons of most patients with AD. Knockout of the *CTSB* gene in these WT hAPP AD mice reduced human A $\beta$ 40 and A $\beta$ 42 by 70%, reduced CTF $\beta$  by 40%, and increased sAPP $\alpha$  by 60% compared with control hAPP mice (Hook et al., 2009). The reduction in A $\beta$  and CTF $\beta$  showed that the *CTSB* gene deletion reduced  $\beta$ -secretase activity for processing the WT  $\beta$ -secretase cleavage site of APP for A $\beta$  production. The increase in sAPP $\alpha$  in these *CTSB* KO hAPP AD mice are consistent with increased availability of APP for nonamyloidogenic processing by  $\alpha$ -secretase, which cleaves within the A $\beta$  peptide sequence. These data provide support for *CTSB*-dependent WT  $\beta$ -secretase activity involved in A $\beta$  production in the brain (Hook et al., 2009).

Whereas WT hAPP-695 mice do not develop memory deficits (Mucke et al., 1994), mice expressing hAPP-695 with the WT  $\beta$ -secretase site and London

## APP-695 and APP-751/770 Expression and Processing in Normal and Transgenic Mouse Models of Alzheimer's Disease



**Fig. 4.** APP-695 and APP-751/770 expression and processing in normal and transgenic mouse models of Alzheimer's disease. (A) Mouse APP-695 (mAPP-695) isoform: (i) normal neuronal expression of mAPP-695 produces mouse A $\beta$  (mA $\beta$ ) and (ii) transgenic neuronal expression of human APP-695 (hAPP-695), driven by the PDGF promoter, produces human A $\beta$  (hA $\beta$ ). Panel (i) shows that in normal mouse brain, APP-695 is exclusively expressed in neurons for the production of amyloidogenic A $\beta$  peptides, reported by several studies (Sandbrink et al., 1993; Rohan de Silva et al., 1997). APP-695 is the most abundant APP isoform expressed in the normal brain (Tanaka et al., 1989; Kang and Müller-Hill, 1990; Jacobsen et al., 1991; Rockenstein et al., 1995; Nalivaeva and Turner, 2013). Panel (ii) shows that in transgenic mice expressing hAPP-695 driven by the PDGF promoter, hAPP-695 is present in neurons and produces A $\beta$  (Hook et al., 2009; Kindy et al., 2012; Hook et al., 2014b), which models the normal (nontransgenic) neuronal expression of hAPP-695 and production of A $\beta$ . (B) Mouse APP-751/770 (mAPP-751/770) isoforms: (i) normal glia expression of mAPP-751/770 produces sAPP $\alpha$  and (ii) transgenic neuronal expression of hAPP-751/770, driven by the PDGF promoter, produces hA $\beta$ . Panel (i) shows that in normal mouse brain, APP-751/770 is expressed in glia cells (Sandbrink et al., 1993) and produces the nonamyloidogenic sAPP $\alpha$  fragment (Kametani et al., 1993; Nalivaeva and Turner, 2013). APP-751/770 is a minor APP isoform in the brain (Tanaka et al., 1989; Kang and Müller-Hill, 1990; Jacobsen et al., 1991; Rockenstein et al., 1995; Nalivaeva and Turner, 2013). Panel (ii) shows that in transgenic mice expressing hAPP-751/770 driven by the PDGF promoter, with deletions of segments within introns 6 and 7 and an insertion (4 bp) in intron 7 (Games et al., 1995; Rockenstein et al., 1995; Mucke et al., 2000; Mueller-Steiner et al., 2006; Wang et al., 2012), hAPP-751/770 is present in neurons and produces A $\beta$ , which differs from the normal (nontransgenic) glia expression of hAPP-751/770 and production of sAPP $\alpha$  (Kametani et al., 1993; Sandbrink et al., 1993; Nalivaeva and Turner, 2013).

mutation of amyloid precursor protein (Lon) near the  $\gamma$ -secretase site sequence (hAPP-WT-Lon-695) display memory loss (Moechars et al., 1999). Thus, this model allows evaluating *CTSB* effects on A $\beta$ , brain plaque, and memory deficits in a model having WT  $\beta$ -secretase activity. *CTSB* KO resulted in substantial improvements in memory deficits and decreased levels of A $\beta$ 42 and A $\beta$ 40 with reduced amyloid plaque load in the hAPP-WT-Lon-695 model (Kindy et al., 2012; Hook et al., 2014b). *CTSB* KO ameliorated memory dysfunction of the hAPP-WT-Lon-695 mice, assessed by Morris water maze behavioral assay, to nearly normal levels of the control WT AD mice (Kindy et al., 2012). Improved memory function was demonstrated by the increased latency time for mice

to swim to a submerged platform (after training) and by the decreased distance traveled by the mice to reach the submerged platform. These results show that the memory impairment in these AD mice was dependent on *CTSB*.

With respect to APP-derived biomarkers, *CTSB* KO in the hAPP-WT-Lon-695 AD mice resulted in decreased brain levels of A $\beta$ 40 and A $\beta$ 42 by ~85%, reduced CTF $\beta$  by 60%, and increased sAPP $\alpha$  by 60% (Kindy et al., 2012). Furthermore, *CTSB* knockout reduced amyloid plaque load by ~85%. The effects of overexpressing the *CTSB* gene were also evaluated in these AD mice; *CTSB* expression resulted in increased levels of A $\beta$ 40 and A $\beta$ 42 that were 50% and 100% above controls (Hook et al., 2014b). These

results demonstrate that CTSSB participates in regulating WT  $\beta$ -secretase activity for  $A\beta$  production.

Importantly, the *CTSSB* KO studies in the transgenic hAPP-WT-Lon-695 AD mice demonstrate that memory deficits and  $A\beta$  production were dependent on CTSSB. These findings led to the authors' conclusion that "[CTSSB] may be an effective drug target for improving memory deficits in most AD patients" (Kindy et al., 2012, Abstract, last line).

### 3. Major Cathepsin B Dependency of Pyroglutamate Amyloid- $\beta$ in Human Amyloid Precursor Protein with Wild-Type $\beta$ -Secretase Site Sequence and Amyloid Precursor Protein Isoform 695 Alzheimer's Disease Model.

Human AD brains possess elevated levels of truncated pyroglutamate-modified amyloid-beta (pGlu- $A\beta$ )(3–40) and pGlu- $A\beta$ (3–42) peptides that contribute to neurotoxicity (Mori et al., 1992; Saido et al., 1995; Iwatsubo et al., 1996). The pGlu- $A\beta$ (3–42) species are a dominant fraction of  $A\beta$  forms in human brains with AD (Hosoda et al., 1998; Harigaya et al., 2000; Piccini et al., 2005; Portelius et al., 2010). The pGlu- $A\beta$ (3–40/42) peptides enhance aggregation of  $A\beta$  peptides to result in greater neurotoxicity (Saido et al., 1996; Russo et al., 2002; Schilling et al., 2006; Nussbaum et al., 2012). Therefore, there is keen interest in the field to find approaches to reduce pGlu- $A\beta$  peptides as a therapeutic approach (Jawhar et al., 2011; Cynis et al., 2016; Hettmann et al., 2020).

The hAPP-WT-Lon-695 AD model discussed above produces pGlu- $A\beta$  (Tanghe et al., 2010). Significantly, the Hook group showed that *CTSSB* KO results in substantial decreases in pGlu- $A\beta$ (3–40) and pGlu- $A\beta$ (3–42) by 65% and 90%, respectively, in the hAPP-WT-Lon-695 mouse model of AD (Hook et al., 2014b). Knockout of *CTSSB* also reduced pGlu- $A\beta$  amyloid plaque load by 46% in the brain. These data demonstrate the CTSSB dependence of pGlu $A\beta$  production and pGlu $A\beta$  amyloid plaque accumulation.

Overexpression of human CTSSB increased pGlu- $A\beta$ (3–40) and pGlu- $A\beta$ (3–42) by 50% and 100%, respectively, and increased  $A\beta$ (1–40), and  $A\beta$ (1–42) by 50% and 100%, respectively, relative to control AD mice (Hook et al., 2014b). Overexpression of CTSSB also increased pGlu plaque load by 178% relative to controls. These data show that CTSSB drives pGlu- $A\beta$  and  $A\beta$  production.

Formation of the pGlu- $A\beta$  peptides utilizes the N-truncated  $A\beta$ (3–40) and  $A\beta$ (3–42) as substrates for N-terminal cyclization of glutamate by glutaminyl cyclase (QC) to generate pGlu- $A\beta$ (3–40) and pGlu- $A\beta$ (3–42) (Schilling et al., 2004; Cynis et al., 2008). The QC substrates may be generated by  $\beta$ -secretase cleavage of APP to produce  $A\beta$ (1–40) and  $A\beta$ (1–42) followed by aminopeptidase removal of N-terminal residues to generate  $A\beta$ (3–40) and  $A\beta$ (3–42). Recently, meprin was found to function as both endopeptidase and N-

terminal dipeptidyl peptidase to generate the N-truncated  $A\beta$  substrates for QC formation of pGlu- $A\beta$  peptides (Schlenzig et al., 2018). Alternatively, direct cleavage of APP could produce  $A\beta$ (3–40) and  $A\beta$ (3–42). It will be of interest to define the proteolytic mechanisms for pGlu- $A\beta$  formation to understand how CTSSB participates in pGlu- $A\beta$  peptide production.

The significant reduction of neurotoxic pGlu- $A\beta$  peptides by *CTSSB* KO led the authors to conclude that CTSSB inhibitors "have potential as new AD therapeutics based on their ability to reduce both pGlu- $A\beta$  and  $A\beta$  produced from  $A\beta$ PP containing the [wild-type]  $\beta$ -secretase site expressed in the majority of AD patients" (Hook et al., 2014b, Discussion, last paragraph, last sentence).

### 4. Minor Cathepsin B Dependency of Amyloid- $\beta$ Degradation in Human Amyloid Precursor Protein with Wild-Type $\beta$ -Secretase Site Sequence and Amyloid Precursor Protein Isoforms 751/770 Alzheimer's Disease Model.

Brain  $A\beta$  was studied in *CTSSB* KO mice expressing the hAPP-WT-751/770 transgene (known as PDAPP hAPP-WT-751/770 mice) by the Gan group. *CTSSB* knockout in these engineered mice resulted in small increases of  $A\beta$ (1–42) in cortex,  $A\beta$ (1–x) in cortex, and hippocampal  $A\beta$ (1–x) brain regions that were 12%, 24%, and 18%, respectively, above controls (Wang et al., 2012). But *CTSSB* KO had no effects on hippocampal  $A\beta$ (1–42). There were no changes in cortical CTF $\beta$  or sAPP $\alpha$  resulting from the *CTSSB* KO condition (Wang et al., 2012). These findings lead to the conclusion that CTSSB was not involved in WT hAPP-751/550 conversion to  $A\beta$  and that CTSSB had a minor role in degrading  $A\beta$  in the hAPP-WT-751/770 expressing mice.

Overexpressing CTSSB in the hAPP-WT-751/770 mice resulted in small decreases in brain  $A\beta$ (1–42) in hippocampus and cortex (by 20% and 9%, respectively), combined with no change in  $A\beta$ (1–x) in hippocampus and cortex, and no change in  $\beta$ -CTF $\beta$  or  $\alpha$ -CTF in cortex relative to controls (Wang et al., 2012). In vitro assays showed that CTSSB can degrade  $A\beta$ . These data implicate a modest role for CTSSB degradation of brain  $A\beta$ (1–42) in mice expressing the hAPP-751/770 isoforms (Wang et al., 2012).

Elevation of CTSSB activity was also achieved by knocking out the cysteine protease inhibitor of CTSSB, cystatin C, in the hAPP-WT-751/770 transgenic mice (Wang et al., 2012). The absence of the endogenous CTSSB inhibitor resulted in modest reductions of  $A\beta$ (1–42) and  $A\beta$ (1–x) by 14% and 6%, respectively, in brain cortex. These results also suggested that CTSSB has a small role in  $A\beta$  degradation. But in addition to CTSSB, other proteases for  $A\beta$  degradation may participate since cystatin C inhibits several cysteine proteases including cathepsins L, S, and H (Barrett,

1986; Abrahamson, 1994). Results from studies of the hAPP-WT-751/770 mice suggested that CTSSB did not affect processing of the hAPP-751/770 isoforms and that CTSSB has a modest role in A $\beta$  degradation (Wang et al., 2012). The authors concluded that “enhancing [CTSSB] could lower A $\beta$ , especially A $\beta$ 42, in AD patients” (Wang et al., 2012, Abstract, last line).

It must be noted that studies of the hAPP-WT-751/770 mice did not assess memory function, (Wang et al., 2012) and, therefore, the role of the hAPP-WT-751/770 isoform and modest effects on A $\beta$  in cognitive deficits is unknown. Evaluation of memory function in the CTSSB KO condition of hAPP-WT-751/770 mice will be important in future studies.

*5. Differences in Cathepsin B Dependency of Amyloid- $\beta$  in Human Amyloid Precursor Protein with Wild-Type  $\beta$ -Secretase Site Sequence Alzheimer’s Disease Models Likely Due to Different Isoforms or Constructs.* As discussed above, the Hook group found a major CTSSB dependence of A $\beta$  production generated from hAPP-695 with the WT  $\beta$ -secretase site sequence (Hook et al., 2009, 2014b; Kindy et al., 2012; Wang et al., 2012), whereas the Gan group found no CTSSB dependency for A $\beta$  production in mice expressing the hAPP-751/770 isoforms with the WT  $\beta$ -secretase site (Wang et al., 2012). The differences in Hook and Gan group data are likely due to the different isoforms and constructs used in the models of the two groups.

The PDGF promoter in the hAPP-695 transgene used by the Hook group resulted in neuronal expression of the transgene. That mimics the native expression of hAPP-695, which is the most abundant brain isoform, expressed exclusively in neurons and is processed into A $\beta$  peptides in the brain (Rockenstein et al., 1995; Belyaev et al., 2010; Nalivaeva and Turner, 2013) (Fig. 4A). As such, the hAPP-WT-Lon-695 precursor is subjected to the endogenous neuronal brain pathways for production of A $\beta$  peptides that occur in vivo in AD. Notably, knockout of CTSSB KO in the hAPP-WT-Lon-695 AD mice resulted in substantial reductions in A $\beta$ 1–40, A $\beta$ 1–42, and amyloid plaque load in the brain and significant improvements in memory deficits (Hook et al., 2009, 2014b; Kindy et al., 2012). Therefore, the CTSSB dependency for A $\beta$  production and memory deficits in the hAPP-WT-Lon-695 AD mice represents a model representing the main population with AD.

In contrast, the PDGF promoter artificially forced the hAPP-751/770 transgene used in the Gan studies to be expressed at high levels in neurons where these APP isoforms are normally not expressed (Fig. 4B). hAPP-751/770 expression resulted in processing of these APP isoforms to amyloidogenic A $\beta$  (Fig. 4Bii) (Wang et al., 2012), but APP-751/770 isoforms are

normally processed to nonamyloidogenic sAPP $\alpha$  (Fig. 4Bi) (Kametani et al., 1993; Nalivaeva and Turner, 2013). APP-751/770 isoforms in normal mouse and human brain are expressed primarily in glia cells (rather than in neurons) (Sandbrink et al., 1993) for production of nonamyloidogenic sAPP $\alpha$  (Fig. 4Bi). Therefore, the transgenic neuronal hAPP-WT-751/770 expression and production of A $\beta$  does not represent the normal glia expression of hAPP-751/770 and production of sAPP $\alpha$  in the brain. Thus, the transgenic hAPP-WT-751/770 expression may reflect an experimental artifact rather than that which naturally occurs.

The hAPP used by the two groups also differed in the engineered APP gene constructs. The hAPP-695 transgene used by the Hook group contained the naturally occurring sequence that produces hAPP-695 (Hook et al., 2009, 2014b; Kindy et al., 2012). On the other hand, the hAPP-751/770 used by the Gan group was not the naturally occurring sequence but rather a highly engineered gene construct with intronic deletions and insertions (Rockenstein et al., 1995; Mucke et al., 2000; Wang et al., 2012). The differences in the APP gene constructs could have resulted in differences in hAPP processing in AD models used by the Gan group compared with the Hook group.

Importantly, mice expressing the PDGF-driven expression of hAPP-695 transgene in neurons, representing the usual AD condition, show that CTSSB KO results in reduced levels of neurotoxic A $\beta$  peptide.

*6. No Cathepsin B Dependency of Memory Deficits and Amyloid- $\beta$  in Human Amyloid Precursor Protein with Swedish Mutant  $\beta$ -Secretase Site Sequence Models, Representative of Rare Familial Alzheimer’s Disease Patients.* In the hAPP-Swe-Lon-695 AD mice, the Hook group found that CTSSB KO resulted in no change in memory deficits, A $\beta$  peptides (A $\beta$ 40 and A $\beta$ 42), and CTF $\beta$  and sAPP $\alpha$  (Kindy et al., 2012). Studies by the Gan group using hAPP-Swe-Ind-751/770 mice also found no effect of CTSSB KO on A $\beta$  peptide production; memory deficits were not assessed in these mice (Mueller-Steiner et al., 2006). Data shows that CTSSB does not cleave the Swe mutant  $\beta$ -secretase site sequence (Hook et al., 2008a), which provides an explanation for the lack of CTSSB KO effect in models expressing hAPP with Swe $\beta$ -secretase site. But the important point is that such models mimic the A $\beta$  production that only occurs in a few individuals and is, thus, not relevant to most AD patients.

*J. The Consilience of Aging, Chronic Periodontitis-Associated Alzheimer’s Disease, and Transgenic Alzheimer’s Disease Data Are that Memory Deficits Are Cathepsin B Dependent, which Provides Rationale for Cathepsin B Inhibitor Development*

The consilience by numerous studies demonstrates that CTSSB KO improves memory deficits in cognitive aging, chronic periodontitis-associated AD, and AD of

representative animal models (Table 4) (Terada et al., 2010; Kindy et al., 2012; Hook et al., 2014b; Ni et al., 2019). The amelioration of memory dysfunction by *CTSB* KO occurred in aged mice but not in young mice and was associated with *CTSB*-dependent reductions in the inflammatory biomarkers of IL-1 $\beta$  and TNF- $\alpha$  (Terada et al., 2010; Ni et al., 2019). *CTSB* KO attenuated memory loss in the periodontitis model of AD, induced by PgLPS from *Porphyromonas gingivalis*, in middle-aged mice but not in young mice; *CTSB* KO reduced inflammatory responses, shown by reduction in microglia IL-1 $\beta$ , toll-like receptor 2, as well as A $\beta$ . Importantly, knockout of *CTSB* in the hAPP-WT-Lon-695 AD mouse model resulted in substantial improvement in memory deficits to levels similar to that of normal mice (Kindy et al., 2012), accompanied by *CTSB*-dependent reductions in the neurotoxic A $\beta$  peptides consisting of A $\beta$ 42, A $\beta$ 40, pGlu-A $\beta$ (3–42) and pGlu-A $\beta$ (3–40) (Kindy et al., 2012; Hook et al., 2014b).

In the AD model studies, improvements in memory deficits by *CTSB* KO occurred in transgenic mice expressing the WT  $\beta$ -secretase site of the hAPP-WT-Lon-695 AD mice, which represents the majority of patients with AD of the sporadic type (>95%) (Masters et al., 2015) who express hAPP with the WT  $\beta$ -secretase site. Therefore, effective amelioration of memory deficits in the *CTSB* KO studies in the hAPP-WT-Lon-695 AD mice is relevant to the major population with AD. Importantly, the *CTSB* KO findings indicate *CTSB* as an excellent candidate drug target for development of inhibitors as a therapeutic approach for AD.

### **IX. Cathepsin B Upregulation Is a Common Response in Neurologic Disorders and Causes Cellular Pathology by Multiple Specific Mechanisms**

*CTSB* upregulation is a common response in neurologic disorders as shown by a wide range of neuropathological conditions in such brain diseases (Table 2). Innate and adaptive immune activation occurs in response to a wide range of damage and infectious signals and results in *CTSB* upregulation (Yan et al., 2020). Activation of the immune system may be a common mechanism by which the diverse neuropathologies cause *CTSB* activation, but more research is needed to determine if that is the case. Regardless, the upregulated and uncontrolled *CTSB* activity that accompanies the neuropathology causes cellular and tissue damage, which can continue long after the precipitating cause has subsided. The *CTSB* KO data show that the *CTSB* activity damages cells and tissues via multiple mechanisms including cellular necrosis, apoptotic cell death, vasculature permeation, microglial activation, NLRP3 inflammasome activation, caspase-1

activation, NF $\kappa$ B activation, overproduction of ROS and cytokines (IL-1 $\beta$ , IL-18, and TNF- $\alpha$ ), selective neuronal autophagy activation, nuclear sirtuins degradation, and A $\beta$  production and degradation. The extent and importance of each specific mechanism by which *CTSB* damages cells likely varies with the neuropathological condition and model. Figure 3 summarizes many of these mechanisms of action mediated by *CTSB*, and Table 3 summarizes how elimination of the *CTSB* gene improves behavioral and pathologic phenotypes in several brain disorder models.


### **X. Summary and Conclusion: Cathepsin B Knockout Data Validates Cathepsin B as a Drug Target for Development of Cathepsin B Inhibitors as Potentially New Therapeutics for Neurologic Disorders**

The aggregate of the *CTSB* gene knockout studies demonstrate the prominent role of *CTSB* in mediating the behavioral deficits, inflammation, and cell death in a multitude of neurologic disease animal models of Alzheimer's disease, periodontitis AD, aging, traumatic brain injury, ischemia, epilepsy, inflammatory pain, and opioid tolerance. The main conclusion is that the data consilience shows that (1) the powerful proteolytic activity of *CTSB* becomes increased and uncontrolled in numerous neurologic and aging conditions causing behavioral dysfunction and neuropathology and (2) *CTSB* gene KO in these models results in substantial improvements in behavioral deficits and amelioration of pathology (Fig. 5). These *CTSB* KO animal studies advance our understanding of the role of *CTSB* upregulation in patients with these neurologic diseases, supporting the hypothesis that these human brain disorders are dependent on *CTSB* mechanisms in memory deficits, motor dysfunction, cell loss, neuroinflammation, and neuropathology. Significantly, *CTSB* inhibition has merit and therapeutic potential for drug treatment of many neurologic disease conditions. Importantly, mice lacking the *CTSB* gene are healthy and generally indistinguishable from normal wild-type animals, which predicts the safety of *CTSB* inhibitors. It is noted that alternative suggestions in the field for activation of *CTSB* as a therapeutic approach in various diseases are not desirable because *CTSB* promotes the detrimental condition of cancer (Buck et al., 1992; Vasiljeva et al., 2008; Gopinathan et al., 2012).

Indeed, chemical inhibition of *CTSB* for improvement of behavioral deficits and neuropathology of brain disorders has been investigated in the field for Alzheimer's disease (Hook et al., 2005, 2007, 2008b, 2011 2014b), TBI and brain trauma (Knoblach et al., 2004; Sun et al., 2013; Luo et al., 2010; Hook et al., 2014a; Ni et al., 2012), ischemia (Inuzuka et al., 1990; Yamashima et al., 1998; Tsuchiya et al., 1999; Seyfried et al., 2001; Yoshida et al.,



## CTSB-Dependent Behavioral Deficits and Pathology in Neurologic Disease Models



\*Alzheimer's disease, inflammation in aging and periodontitis AD, traumatic brain injury, ischemia, epilepsy, multiple sclerosis, inflammatory pain, tolerance to opioid

**Fig. 5.** The consilience of *CTSB* KO data in neurologic disorders modeled in mice demonstrate CTSB-dependent behavioral deficits and pathology. Evidence for elevation of CTSB in models of brain disorders and amelioration of behavioral deficits and neuropathology by *CTSB* gene knockout in these models is summarized in this figure. (A) Elevation of CTSB expression results in several behavioral deficits and pathology in several neurologic disorders modeled in mice. Increased levels of CTSB in the brain occurs in numerous neurologic disorders modeled in mice (Table 2). The elevated CTSB in the animal models of brain disorders parallels the increased CTSB found in numerous patients with clinical neurologic disease (Table 1). (B) *CTSB* gene KO results in substantial improvements in behavioral deficits and pathology of several neurologic disorders modeled in mice. The consilience of results of *CTSB* gene KO studies in numerous animal models of neurologic disease demonstrate that the absence of CTSB results in substantial improvements in behavioral deficits and pathology (Tables 3 and 4).

2002; Tsubokawa et al., 2006), pain (Sun et al., 2012; Nakanishi, 2020), meningitis (Ruff and Secrist, 1984), and other neurologic and neurodegenerative disease animal models (reviewed in Hook et al., 2020; Sharma et al., 2022). These studies have used (a) the selective CTSB inhibitor, CA-074 (Murata et al., 1991; Towatari et al., 1991), administered *in vivo* to animal models as the pro-drug form of CA-074Me (Buttle et al., 1992), (b) the pan-cysteine protease inhibitor E64c (Hashida et al., 1980; Tamai et al., 1986), administered as its prodrug form of E64d, and (c) other inhibitors of CTSB, such as K11777 (Turk et al., 2012), Z-Phe-Arg-FMK (Wang et al., 2006), and other related inhibitors. These CTSB inhibitor studies are summarized in a recent review (Hook et al., 2020).

In summary, the strong evidence for CTSB participation in numerous neurologic disease conditions and efforts in the field for development of chemical inhibitors of CTSB for therapeutics support the hypothesis that CTSB inhibitors can be developed as therapeutic agents for treatment of CTSB-dependent neurologic disease deficits.

## XI. Significance

The significance of this review is in its comprehensive compilation of the extensive data that together point to inhibition of the CTSB target as the logical approach for therapeutics development for the plethora of CTSB-dependent neurologic disease conditions. The extensive

experimental evidence in support of inhibition of CTSB as the best therapeutic approach for these diseases addresses an ongoing debate in the CTSB research community as to whether CTSB inhibition or activation is the appropriate therapeutic approach. The consilience of the majority of data demonstrates the significant conclusion that inhibition of the CTSB target provides a new opportunity to address the lack of drug treatments available that are needed to improve patient health in neurologic disease conditions.

### Acknowledgments

Figure 2 is adapted from Hook et al., 2015, DOI: 10.3389/fneur.2015.00178, originally published by Frontiers. The Frontiers policy states that "The CC-BY Creative Commons attribution license enables anyone to sue the publication freely, given appropriate attribution to the authors and citing Frontiers as the original publisher."

### Authorship Contributions

Wrote or contributed to the writing of the manuscript: G. Hook, Reinheckel, Ni, Wu, Peters, V. Hook.

### References

- Abrahamson M (1994). Cystatins. *Methods Enzymol* **244**:685–700.
- Abrahamson M, Barrett AJ, Salvesen G, and Grubb A (1986) Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. *J Biol Chem* **261**:11282–11289.
- Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. (2000) Inflammation and Alzheimer's disease. *Neurobiol Aging* **21**:383–421.

- Akkari L, Gocheva V, Quick ML, Kester JC, Spencer AK, Garfall AL, Bowman RL, and Joyce JA (2016) Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. *Genes Dev* **30**:220–232.
- Allan ER and Yates RM (2015) Redundancy between cysteine cathepsins in murine experimental autoimmune encephalomyelitis. *PLoS One* **10**:e0128945.
- Andrew RJ, Kellett KA, Thinakaran G, and Hooper NM (2016) A Greek tragedy: the growing complexity of Alzheimer amyloid precursor protein proteolysis. *J Biol Chem* **291**:19235–19244.
- Aoki T, Kataoka H, Ishibashi R, Nozaki K, and Hashimoto N (2008) Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms. *Stroke* **39**:2603–2610.
- Ardura-Fabregat A, Boddeke EWGM, Boza-Serrano A, Brioschi S, Castro-Gomez S, Ceyzériat K, Dansokho C, Dierkes T, Gelders G, Heneka MT, et al. (2017) Targeting neuroinflammation to treat Alzheimer's disease. *CNS Drugs* **31**:1057–1082.
- Armstrong A, Mattsson N, Appelqvist H, Janejford C, Sandin L, Agholme L, Olsson B, Svensson S, Blennow K, Zetterberg H, et al. (2014) Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease. *Neuromolecular Med* **16**:150–160.
- Aronson Jr NN and Barrett AJ (1978) The specificity of cathepsin B. Hydrolysis of glucagon at the C-terminus by a peptidyl dipeptidase mechanism. *Biochem J* **171**:759–765.
- Assfalg-Machleidt I, Jochum M, Nast-Kolb D, Siebeck M, Billing A, Joka T, Rothe G, Valet G, Zauner R, Scheuber HP, et al. (1990) Cathepsin B-indicator for the release of lysosomal cysteine proteinases in severe trauma and inflammation. *Biol Chem Hoppe Seyler* **371** (Suppl):211–222.
- Bai H, Yang B, Yu W, Xiao Y, Yu D, and Zhang Q (2018) Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome. *Exp Cell Res* **362**:180–187.
- Barrett AJ (1986) The cystatins: a diverse superfamily of cysteine peptidase inhibitors. *Biomed Biochim Acta* **45**:1363–1374.
- Batkulwar K, Godbole R, Banarjee R, Kassar O, Williams RJ, and Kulkarni MJ (2018) Advanced glycation end products modulate amyloidogenic APP processing and tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer's disease. *ACS Chem Neurosci* **9**:988–1000.
- Becker-Pauly C and Pietrzyk CU (2017) The metalloprotease meprin  $\beta$  is an alternative  $\beta$ -secretase of APP. *Front Mol Neurosci* **9**:159.
- Belyaev ND, Kellett KA, Beckett K, Makova NZ, Revett TJ, Nalivaeva NN, Hooper NM, and Turner AJ (2010) The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a beta-secretase-dependent pathway. *J Biol Chem* **285**:41443–41454.
- Ben Khalifa N, Tyteca D, Marinangeli C, Depuydt M, Collet JF, Courtoy PJ, Renaud JC, Constantinescu S, Octave JN, and Kienlen-Campard P (2012) Structural features of the KPI domain control APP dimerization, trafficking, and processing. *FASEB J* **26**:855–867.
- Bernstein HG, Kirschke H, Wiederanders B, Schmidt D, and Rinne A (1990) Antigenic expression of cathepsin B in aged human brain. *Brain Res Bull* **24**:543–549.
- Bestvater F, Dallner C, and Spiess E (2005) The C-terminal subunit of artificially truncated human cathepsin B mediates its nuclear targeting and contributes to cell viability. *BMC Cell Biol* **6**:16.
- Blott EJ and Griffiths GM (2002) Secretory lysosomes. *Nat Rev Mol Cell Biol* **3**:122–131.
- Bouter Y, Kacprowski T, Weissmann R, Dietrich K, Borgers H, Brauß A, Sperling C, Wirths O, Albrecht M, Jensen LR, et al. (2014) Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing. *Front Aging Neurosci* **6**:75.
- Boutté AM, Hook V, Thangavelu B, Sarkis GA, Abbatiello BN, Hook G, Jacobsen JS, Robertson CS, Gilsdorf J, Yang Z, et al. (2020) Penetrating traumatic brain injury triggers dysregulation of cathepsin B protein levels independent of cysteine protease activity in brain and cerebral spinal fluid. *J Neurotrauma* **37**:1574–1586.
- Bron JP, Couck AM, Bruce M, Anderton B, and Flament-Durand J (1991) Synaptophysin and chromogranin A immunoreactivities in senile plaques of Alzheimer's disease. *Brain Res* **539**:143–150.
- Brommage R, Powell DR, and Vogel P (2019) Predicting human disease mutations and identifying drug targets from mouse gene knockout phenotyping campaigns. *Dis Model Mech* **12**:dmm038224.
- Brooks SP, Pask T, Jones L, and Dunnett SB (2005) Behavioural profiles of inbred mouse strains used as transgenic backgrounds. II: cognitive tests. *Genes Brain Behav* **4**:307–317.
- Broom DC, Samad TA, Kohno T, Tegeder I, Geisslinger G, and Woolf CJ (2004) Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. *Neuroscience* **124**:891–900.
- Bryant CD, Zhang NN, Sokoloff G, Fanselow MS, Ennes HS, Palmer AA, and McRoberts JA (2008) Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. *J Neurogenet* **22**:315–331.
- Buck MR, Karustis DG, Day NA, Honn KV, and Sloane BF (1992) Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. *Biochem J* **282**:273–278.
- Buttle DJ, Murata M, Knight CG, and Barrett AJ (1992) CA074 methyl ester: a proinhibitor for intracellular cathepsin B. *Arch Biochem Biophys* **299**:377–380.
- Campden RI and Zhang Y (2019) The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation. *Arch Biochem Biophys* **670**:32–42.
- Cantres-Rosario Y, Plaud-Valentin M, Gerena Y, Skolasky RL, Wojna V, and Meléndez LM (2013) Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders. *AIDS* **27**:347–356.
- Carniglia L, Ramirez D, Durand D, Saba J, Turati J, Caruso C, Scimonelli TN, and Lasaga M (2017) Neuropeptides and microglial activation in inflammation, pain, and neurodegenerative diseases. *Mediators Inflamm* **2017**:5048616.
- Cataldo AM and Nixon RA (1990) Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. *Proc Natl Acad Sci USA* **87**:3861–3865.
- Chan SJ, San Segundo B, McCormick MB, and Steiner DF (1986) Nucleotide and predicted amino acid sequences of cloned human and mouse preprocathepsin B cDNAs. *Proc Natl Acad Sci USA* **83**:7721–7725.
- Chiappini C, Campagnolo P, Almeida CS, Abbassi-Ghadi N, Chow LW, Hanna GB, and Stevens MM (2015) Mapping local cytosolic enzymatic activity in human esophageal mucosa with porous silicon nanoneedles. *Adv Mater* **27**:5147–5152.
- Choe Y, Leonetti F, Greenbaum DC, Lecaille F, Bogoy M, Brömme D, Ellman JA, and Craik CS (2006) Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. *J Biol Chem* **281**:12824–12832.
- Christian F, Smith EL, and Carmody RJ (2016) The regulation of NF- $\kappa$ B subunits by phosphorylation. *Cells* **5**:12.
- Cordy JM, Hussain I, Dingwall C, Hooper NM, and Turner AJ (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. *Proc Natl Acad Sci USA* **100**:11735–11740.
- Correale J, Gaitán MI, Ysraelit MC, and Fiol MP (2017) Progressive multiple sclerosis: from pathogenic mechanisms to treatment. *Brain* **140**:527–546.
- Cynis H, Frost JL, Crehan H, and Lemere CA (2016) Immunotherapy targeting pyroglutamate-3 A $\beta$ : prospects and challenges. *Mol Neurodegener* **11**:48.
- Cynis H, Scheel E, Saïdo TC, Schilling S, and Demuth HU (2008) Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. *Biochemistry* **47**:7405–7413.
- Czibere L, Baur LA, Wittmann A, Gemmeke K, Steiner A, Weber P, Pütz B, Ahmad N, Bunck M, Graf C, et al. (2011) Profiling trait anxiety: transcriptome analysis reveals cathepsin B (Ctbs) as a novel candidate gene for emotionality in mice. *PLoS One* **6**:e23604.
- Dangond F, Hwang D, Camelo S, Pasinelli P, Frosch MP, Stephanopoulos G, Stephanopoulos G, Brown Jr RH, and Gullans SR (2004) Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. *Physiol Genomics* **16**:229–239.
- de Castro MA, Bunt G, and Wouters FS (2016) Cathepsin B launches an apoptotic exit effort upon cell death-associated disruption of lysosomes. *Cell Death Discov* **2**:16012.
- Deussing J, Roth W, Rommerskirch W, Wiederanders B, von Figura K, and Peters C (1997) The genes of the lysosomal cysteine proteinases cathepsin B, H, L, and S map to different mouse chromosomes. *Mamm Genome* **8**:241–245.
- Dixon KJ (2017) Pathophysiology of traumatic brain injury. *Phys Med Rehabil Clin N Am* **28**:215–225.
- du Plessis AJ and Volpe JJ (2002) Perinatal brain injury in the preterm and term newborn. *Curr Opin Neurol* **15**:151–157.
- Ehehalt R, Keller P, Haass C, Thiele C, and Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. *J Cell Biol* **160**:113–123.
- Ellis RC, Earnhardt JN, Hayes RL, Wang KK, and Anderson DK (2004) Cathepsin B mRNA and protein expression following contusion spinal cord injury in rats. *J Neurochem* **88**:689–697.
- Ellis RC, O'Steen WA, Hayes RL, Nick HS, Wang KK, and Anderson DK (2005) Cellular localization and enzymatic activity of cathepsin B after spinal cord injury in the rat. *Exp Neurol* **193**:19–28.
- Faul M, Xu LX, Wald M, and Coronado V (2010) *Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths 2002–2006*, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, GA, [https://www.cdc.gov/traumaticbraininjury/pdf/blue\\_book.pdf](https://www.cdc.gov/traumaticbraininjury/pdf/blue_book.pdf).
- Felber U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, and Olsen BR (2002) Neuronal loss and brain atrophy in mice lacking cathepsins B and L. *Proc Natl Acad Sci USA* **99**:7883–7888.
- Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, and Shaw PJ (2007) Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. *J Neurosci* **27**:9201–9219.
- Festing MFW (1992) *Techniques for the Genetic Analysis of Brain and Behavior: Focus on the Mouse* (Goldowiz D, Wahlsten D, and Wimer RE, eds) pp 17–38, Elsevier, Amsterdam, Netherlands.
- Fissolo N, Kraus M, Reich M, Ayturan M, Overkleef H, Driessen C, and Weissert R (2008) Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. *Eur J Immunol* **38**:2401–2411.
- Friedrichs B, Tepel C, Reinheckel T, Deussing J, von Figura K, Herzog V, Peters C, Saftig P, and Brix K (2003) Thyroid functions of mouse cathepsins B, K, and L. *J Clin Invest* **111**:1733–1745.
- Fong D, Chan MM, Hsieh WT, Menninger JC, and Ward DC (1992) Confirmation of the human cathepsin B gene (CTSB) assignment to chromosome 8. *Hum Genet* **89**:10–12.
- Fruton JS and Bergmann M (1939) On the proteolytic enzymes of animal tissues: beef spleen. *J Biol Chem* **130**:19–27.
- Gabrijelcic D, Gollwitzer R, Popović T, and Turk V (1988) Proteolytic cleavage of human fibrinogen by cathepsin B. *Biol Chem Hoppe Seyler* **369** (Suppl):287–292.
- Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. *Nature* **373**:523–527.
- García-González L, Pilat D, Baranger K, and Rivera S (2019) Emerging alternative proteinases in APP metabolism and Alzheimer's disease pathogenesis: a focus on MT1-MMP and MT5-MMP. *Front Aging Neurosci* **11**:244.
- Gerlai R (1996) Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? *Trends Neurosci* **19**:177–181.

- Ghosh G, Wang VY, Huang DB, and Fusco A (2012) NF- $\kappa$ B regulation: lessons from structures. *Immunol Rev* **246**:36–58.
- Gong Q, Chan SJ, Bajkowski AS, Steiner DF, and Frankfater A (1993) Characterization of the cathepsin B gene and multiple mRNAs in human tissues: evidence for alternative splicing of cathepsin B pre-mRNA. *DNA Cell Biol* **12**:299–309.
- Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T, and Tuveson DA (2012) Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. *Gut* **61**:877–884. doi:10.1136/gutjnl-2011-300850.
- Gosalia DN, Salisbury CM, Ellman JA, and Diamond SL (2005) High throughput substrate specificity profiling of serine and cysteine proteases using solution-phase fluorogenic peptide microarrays. *Mol Cell Proteomics* **4**:626–636.
- Halang W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenburger M, Reinheckel T, Domschke W, Lippert H, Peters C, and Deussing J (2000) Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. *J Clin Invest* **106**:773–781.
- Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, and Golenbock DT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. *Nat Immunol* **9**:857–865.
- Hämälistö S, Stahl JL, Favaro E, Yang Q, Liu B, Christoffersen L, Loos B, Guasch Boldú C, Joyce JA, Reinheckel T, et al. (2020) Spatially and temporally defined lysosomal leakage facilitates mitotic chromosome segregation. *Nat Commun* **11**:229.
- Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, Zhou J, Yan R, Vanmechelen E, De Vos A, et al. (2021) The  $\beta$ -secretase BACE1 in Alzheimer's disease. *Biol Psychiatry* **89**:745–756.
- Hanewinkel H, Glössl J, and Kresse H (1987) Biosynthesis of cathepsin B in cultured normal and I-cell fibroblasts. *J Biol Chem* **262**:12351–12355.
- Hansen T (2007) The Nobel Prize in physiology or medicine 2007. *Scand J Immunol* **66**:603.
- Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, and Younkin SG (2000) Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. *Biochem Biophys Res Commun* **276**:422–427.
- Hasanbasic S, Jahic A, Karahmet E, Sejranic A, and Prnjavorac B (2016) The role of cysteine protease in Alzheimer disease. *Mater Sociomed* **28**:235–238.
- Hashida S, Towatari T, Kominami E, and Katunuma N (1980) Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo. *J Biochem* **88**:1805–1811.
- Hayashi Y, Koga Y, Zhang X, Peters C, Yanagawa Y, Wu Z, Yokoyama T, and Nakanishi H (2014) Autophagy in superficial spinal dorsal horn accelerates the cathepsin B-dependent morphine antinociceptive tolerance. *Neuroscience* **275**:384–394.
- Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. (2015) Neuroinflammation in Alzheimer's disease. *Lancet Neurol* **14**:388–405.
- Hentze H, Lin XY, Choi MS, and Porter AG (2003) Critical role for cathepsin B in mediating caspase-1-dependent interleukin-18 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin. *Cell Death Differ* **10**:956–968.
- Hernandez ML, Chatlos T, Gorse KM, and Lafrenaye AD (2019) Neuronal membrane disruption occurs late following diffuse brain trauma in rats and involves a subpopulation of NeuN negative cortical neurons. *Front Neurol* **10**:1238.
- Hettmann T, Gillies SD, Kleinschmidt M, Piechotta A, Makioka K, Lemere CA, Schilling S, Rahfeld JU, and Lues I (2020) Development of the clinical candidate PBD-C06, a humanized pGlu3-A $\beta$ -specific antibody against Alzheimer's disease with reduced complement activation. *Sci Rep* **10**:3294.
- Hoegen T, Tremel N, Klein M, Angele B, Wagner H, Kirschnig C, Pfister HW, Fontana A, Hammerschmidt S, and Koedel U (2011) The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release. *J Immunol* **187**:5440–5451.
- Hook G, Hook V, and Kindy M (2011) The cysteine protease inhibitor, E64d, reduces brain amyloid- $\beta$  and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1,  $\beta$ -secretase activity. *J Alzheimers Dis* **26**:387–408.
- Hook G, Jacobsen JS, Grabstein K, Kindy M, and Hook V (2015) Cathepsin B is a new drug target for traumatic brain injury therapeutics: evidence for E64d as a promising lead drug candidate. *Front Neurol* **6**:178.
- Hook GR, Yu J, Sipes N, Pierschbacher MD, Hook V, and Kindy MS (2014a) The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury. *J Neurotrauma* **31**:515–529.
- Hook G, Yu J, Toneff T, Kindy M, and Hook V (2014b) Brain pyroglutamate amyloid- $\beta$  is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. *J Alzheimers Dis* **41**:129–149.
- Hook V, Kindy M, and Hook G (2007) Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. *Biol Chem* **388**:247–252.
- Hook VY, Kindy M, and Hook G (2008a) Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. *J Biol Chem* **283**:7745–7753.
- Hook VY, Kindy M, Reinheckel T, Peters C, and Hook G (2009) Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. *Biochem Biophys Res Commun* **386**:284–288.
- Hook VY and Reisine TD (2003) Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. *J Neurosci Res* **74**:393–405.
- Hook V, Schechter I, Demuth HU, and Hook G (2008b) Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. *Biol Chem* **389**:993–1006.
- Hook V, Toneff T, Bogoy M, Greenbaum D, Medzhradszky KF, Neveu J, Lane W, Hook G, and Reisine T (2005) Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. *Biol Chem* **386**:931–940.
- Hook V, Yoon M, Mosier C, Ito G, Podvin S, Head BP, Rissman R, O'Donoghue AJ, and Hook G (2020) Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders. *Biochim Biophys Acta Proteins Proteomics* **1868**:140428.
- Hosoda R, Saido TC, Otvos Jr L, Arai T, Mann DM, Lee VM, Trojanowski JQ, and Iwatsubo T (1998) Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. *J Neuropathol Exp Neurol* **57**:1089–1095.
- Houseweart MK, Pennacchio LA, Vilaythong A, Peters C, Noebels JL, and Myers RM (2003) Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). *J Neurobiol* **56**:315–327.
- Howie AJ, Burnett D, and Crocker J (1985) The distribution of cathepsin B in human tissues. *J Pathol* **145**:307–314.
- Hsu A, Podvin S, and Hook V (2018) Lysosomal cathepsin protease gene expression profiles in the human brain during normal development. *J Mol Neurosci* **65**:420–431.
- Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, and Chen J (2012) Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. *Stroke* **43**:3063–3070.
- Hummel III RP, James JH, Warner BW, Hasselgren PO, and Fischer JE (1988) Evidence that cathepsin B contributes to skeletal muscle protein breakdown during sepsis. *Arch Surg* **123**:221–224.
- Hwang SR, Stoka V, Turk V, and Hook VY (2005) The novel bovine serpin endopin 2C demonstrates selective inhibition of the cysteine protease cathepsin L compared to the serine protease elastase, in cross-class inhibition. *Biochemistry* **44**:7757–7767.
- Hyder AA, Wunderlich CA, Puvanachandra P, Gururaj G, and Kobusingye OC (2007) The impact of traumatic brain injuries: a global perspective. *NeuroRehabilitation* **22**:341–353.
- Illy C, Quraishi O, Wang J, Purisima E, Vernet T, and Mort JS (1997) Role of the occluding loop in cathepsin B activity. *J Biol Chem* **272**:1197–1202.
- Inuzuka T, Tamura A, Sato S, Kirino T, Toyoshima I, and Miyatake T (1990) Suppressive effect of E-64c on ischemic degradation of cerebral proteins following occlusion of the middle cerebral artery in rats. *Brain Res* **526**:177–179.
- Isbert S, Wagner K, Eggert S, Schweitzer A, Multhaup G, Weggen S, Kins S, and Pietrzik CU (2012) APP dimer formation is initiated in the endoplasmic reticulum and differs between APP isoforms. *Cell Mol Life Sci* **69**:1353–1375.
- Iwatsubo T, Saido TC, Mann DM, Lee VM, and Trojanowski JQ (1996) Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. *Am J Pathol* **149**:1823–1830.
- Jacobsen JS, Blume AJ, and Vitek MP (1991) Quantitative measurement of alternatively spliced amyloid precursor protein mRNA expression in Alzheimer's disease and normal brain by S1 nuclease protection analysis. *Neurobiol Aging* **12**:585–592.
- Jawhar S, Wirths O, and Bayer TA (2011) Pyroglutamate amyloid- $\beta$  (A $\beta$ ): a hatchet man in Alzheimer disease. *J Biol Chem* **286**:38825–38832.
- Jiang Z, Lietz CB, Podvin S, Yoon MC, Toneff T, Hook V, and O'Donoghue AJ (2021) Differential neuropetides of dense core secretory vesicles (DCSV) produced at intravesicular and extracellular pH conditions by proteolytic processing. *ACS Chem Neurosci* **12**:2385–2398.
- Jochum M, Machleidt W, and Fritzh H (1993) Phagocyte proteinases in multiple trauma and sepsis: pathomechanisms and related therapeutic approaches, in *Handbook of Mediators in Septic Shock*. (Neugebauer EA and Holaday JW, eds) pp 336–361, CRC Press, Boca Raton, FL.
- Jung H, Lee EY, and Lee SI (1999) Age-related changes in ultrastructural features of cathepsin B- and D-containing neurons in rat cerebral cortex. *Brain Res* **844**:43–54.
- Kälviäinen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, and Mervaala E (2008) Clinical picture of EPM1-Unverricht-Lundborg disease. *Epilepsia* **49**:549–556.
- Kametani F, Tanaka K, Ishii T, Ikeda S, Kennedy HE, and Allsop D (1993) Secretory form of Alzheimer amyloid precursor protein 695 in human brain lacks beta/A4 amyloid immunoreactivity. *Biochem Biophys Res Commun* **191**:392–398.
- Kang J and Müller-Hill B (1990) Differential splicing of Alzheimer's disease amyloid A4 precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat and human brain. *Biochem Biophys Res Commun* **166**:1192–1200.
- Katunuma N (2010) Posttranslational processing and modification of cathepsins and cystatins. *J Signal Transduct* **2010**:375345.
- Kawasaki Y, Xu ZZ, Wang X, Park JY, Zhuang ZY, Tan PH, Gao YJ, Roy K, Corfas G, Lo EH, et al. (2008) Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. *Nat Med* **14**:331–336.
- Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, et al. (2011) Non-canonical inflammasome activation targets caspase-11. *Nature* **479**:117–121.
- Ketterer S, Gomez-Auli A, Hillebrand LE, Petrera A, Ketscher A, and Reinheckel T (2017) Inherited diseases caused by mutations in cathepsin protease genes. *FEBS J* **284**:1437–1454.
- Kikuchi H, Yamada T, Furuya H, Doh-ura K, Ohyagi Y, Iwaki T, and Kira J (2003) Involvement of cathepsin B in the motor neuron degeneration of amyotrophic lateral sclerosis. *Acta Neuropathol* **105**:462–468.

- Kindy MS, Yu J, Zhu H, El-Amouri SS, Hook V, and Hook GR (2012) Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A $\beta$ PP containing the wild-type  $\beta$ -secretase site sequence. *J Alzheimers Dis* **29**:827–840.
- Klein DM, Felsenstein KM, and Brenneman DE (2009) Cathepsins B and L differentially regulate amyloid precursor protein processing. *J Pharmacol Exp Ther* **328**:813–821.
- Knobloch SM, Alroy DA, Nikolaeva M, Cernak I, Stoica BA, and Faden AI (2004) Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. *J Cereb Blood Flow Metab* **24**:1119–1132.
- Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E, Gotow T, Peters C, von Figura K, Mizushima N, et al. (2005) Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). *Am J Pathol* **167**:1713–1728.
- Koller BH, Marrack P, Kappler JW, and Smithies O (1990) Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. *Science* **248**:1227–1230.
- Kukor Z, Mayerle J, Krüger B, Tóth M, Steed PM, Halangk W, Lerch MM, and Sahin-Tóth M (2002) Presence of cathepsin B in the human pancreatic secretory pathway and its role in trypsinogen activation during hereditary pancreatitis. *J Biol Chem* **277**:21389–21396.
- Kuliawat R, Klumperman J, Ludwig T, and Arvan P (1997) Differential sorting of lysosomal enzymes out of the regulated secretory pathway in pancreatic beta-cells. *J Cell Biol* **137**:595–608.
- Lafrenaye AD, McGinn MJ, and Povlishock JT (2012) Increased intracranial pressure after diffuse traumatic brain injury exacerbates neuronal somatic membrane poration but not axonal injury: evidence for primary intracranial pressure-induced neuronal perturbation. *J Cereb Blood Flow Metab* **32**:1919–1932.
- Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, et al. (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. *J Neurosci* **25**:11693–11709.
- Lane CA, Hardy J, and Schott JM (2018) Alzheimer's disease. *Eur J Neurol* **25**:59–70.
- Lariviere WR, Chesler EJ, and Mogil JS (2001) Transgenic studies of pain and analgesia: mutation or background genotype? *J Pharmacol Exp Ther* **297**:467–473.
- Li P, Allen H, Banerjee S, Franklin S, Herzig L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, et al. (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. *Cell* **80**:401–411.
- Li X, Wu Z, Ni J, Liu Y, Meng J, Yu W, Nakanishi H, and Zhou Y (2016) Cathepsin B regulates collagen expression by fibroblasts via prolonging TLR2/NF- $\kappa$ B activation. *Oxid Med Cell Longev* **2016**:7894247.
- Lin WJ and Salton SR (2013) The regulated secretory pathway and human disease: insights from gene variants and single nucleotide polymorphisms. *Front Endocrinol (Lausanne)* **4**:96.
- Linebaugh BE, Sameni M, Day NA, Sloane BF, and Keppler D (1999) Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. *Eur J Biochem* **264**:100–109.
- Luo CL, Chen XP, Yang R, Sun YX, Li QQ, Bao HJ, Cao QQ, Ni H, Qin ZH, and Tao LY (2010) Cathepsin B contributes to traumatic brain injury-induced cell death through a mitochondria-mediated apoptotic pathway. *J Neurosci Res* **88**:2847–2858.
- Maciewicz RA, Wotton SF, Etherington DJ, and Duance VC (1990) Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. *FEBS Lett* **269**:189–193.
- Mahurkar S, Idris MM, Reddy DN, Bhaskar S, Rao GV, Thomas V, Singh L, and Chandak GR (2006) Association of cathepsin B gene polymorphisms with tropical calcific pancreatitis. *Gut* **55**:1270–1275.
- Mak TW (2007) Gene targeting in embryonic stem cells scores a knockout in Stockholm. *Cell* **131**:1027–1031.
- Mantle D, Falkous G, Ishiura S, Perry RH, and Perry EK (1995) Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. *J Neurol Sci* **131**:65–70.
- Martinez-Vargas M, Soto-Núñez M, Tabla-Ramon E, Solis B, Gonzalez-Rivera R, Perez-Arredondo A, Estrada-Rojo F, Castell A, Molina-Guarneros J, and Navarro L (2014) Cystatin C has a dual role in post-traumatic brain injury recovery. *Int J Mol Sci* **15**:5807–5820.
- Martinson F, Burns K, and Tschoep J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1 $\beta$ . *Mol Cell* **10**:417–426.
- Martyn JAJ, Mao J, and Bittner EA (2019) Opioid tolerance in critical illness. *N Engl J Med* **380**:365–378.
- Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, and Cummings JL (2015) Alzheimer's disease. *Nat Rev Dis Primers* **1**:15056.
- Meng J, Liu Y, Xie Z, Qing H, Lei P, Ni J (2020) Nucleus distribution of cathepsin B in senescent microglia promotes brain aging through degradation of sirtuins. *Neurobiol Aging* **96**:255–266.
- Moehars D, Dewachter I, Lorent K, Reversé D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, et al. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. *J Biol Chem* **274**:6483–6492.
- Mogil JS and Wilson SG (1997) Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6 inbred mouse strains: implications for transgenic knock-out studies. *Eur J Pain* **1**:293–297.
- Mohamad J, Samuelov L, Malki L, Peled A, Pavlovsky M, Malovitski K, Taiber S, Adir N, Rabinowitz T, Shomron N, et al. (2021) Palmoplantar keratoderma caused by a missense variant in CTSB encoding cathepsin B. *Clin Exp Dermatol* **46**:103–108.
- Moon HY, Becke A, Berron D, Becker B, Sah N, Benoni G, Janke E, Lubejko ST, Greig NH, Mattison JA, et al. (2016) Running-induced systemic cathepsin B secretion is associated with memory function. *Cell Metab* **24**:332–340.
- Morena F, Argentati C, Trotta R, Crispolti L, Stabile A, Pistilli A, di Baldassarre A, Calafore R, Montanucci P, Basta G, et al. (2017) A comparison of lysosomal enzymes expression levels in peripheral blood of mild- and severe-Alzheimer's disease and MCI patients: implications for regenerative medicine approaches. *Int J Mol Sci* **18**:1806.
- Mori H, Takio K, Ogawara M, and Selkoe DJ (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. *J Biol Chem* **267**:17082–17086.
- Mort JS (2004) Cathepsin B, in *Handbook of Proteolytic Enzymes 2nd Edition* (Barrett AJ, Rawlings ND, and Woessner JF, eds) pp 1079–1086, Elsevier Academic Press, London.
- Mort JS and Buttler DJ (1997) Cathepsin B. *Int J Biochem Cell Biol* **29**:715–720.
- Mort JS, Recklies AD, and Poole AR (1984) Extracellular presence of the lysosomal proteinase cathepsin B in rheumatoid synovium and its activity at neutral pH. *Arthritis Rheum* **27**:509–515.
- Mucke L, Masliah E, Johnson WB, Ruppé MD, Alford M, Rockenstein EM, Fors-Petter S, Pietropaolo M, Mallory M, and Abraham CR (1994) Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. *Brain Res* **666**:151–167.
- Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, and McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. *J Neurosci* **20**:4050–4058.
- Mueller-Stegner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, et al. (2006) Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. *Neuron* **51**:703–714.
- Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, and Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. *Nat Genet* **1**:345–347.
- Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K, Towatari T, Nikawa T, and Katunuma N (1991) Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. *FEBS Lett* **280**:307–310.
- Musil D, Zucic D, Turk D, Engh RA, Mayr I, Huber R, Popovic T, Turk V, Towatari T, Katunuma N, et al. (1991) The refined 2.15 Å X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. *EMBO J* **10**:2321–2330.
- Nagai A, Murakawa Y, Terashima M, Shimode K, Umegae N, Takeuchi H, and Kobayashi S (2000) Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. *Neurology* **55**:1828–1832.
- Nakahara J, Aiso S, and Suzuki N (2010) Autoimmune versus oligodendroglial pathology: the pathogenesis of multiple sclerosis. *Arch Immunol Ther Exp (Warsz)* **58**:325–333.
- Nakanishi H (2020) Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. *Neural Regen Res* **15**:25–29.
- Nakanishi H, Tominaga K, Amano T, Hirotsu I, Inoue T, and Yamamoto K (1994) Age-related changes in activities and localizations of cathepsins D, E, B, and L in the rat brain tissues. *Exp Neurol* **126**:119–128.
- Nalivaeva NN and Turner AJ (2013) The amyloid precursor protein: a biochemical enigma in brain development, function and disease. *FEBS Lett* **587**:2046–2054.
- Natale JE, Ahmed F, Cernak I, Stoica B, and Faden AI (2003) Gene expression profile changes are commonly modulated across models and species after traumatic brain injury. *J Neurotrauma* **20**:907–927.
- Ngungcu T, Oti M, Sitek JC, Haukanes BI, Linghu B, Bruccoleri R, Stokowy T, Oakeley EJ, Yang F, Zhu J, et al. (2017) Duplicated enhancer region increases expression of CTSB and segregates with keratolytic winter erythema in South African and Norwegian families. *Am J Hum Genet* **100**:737–750.
- Ni H, Ren SY, Zhang LL, Sun Q, Tian T, and Feng X (2013) Expression profiles of hippocampal regenerative sprouting-related genes and their regulation by E-64d in a developmental rat model of penicillin-induced recurrent epilepticus. *Toxicol Lett* **217**:162–169.
- Ni H, Yan JZ, Zhang LL, Feng X, and Wu XR (2012) Long-term effects of recurrent neonatal seizures on neurobehavioral function and related gene expression and its intervention by inhibitor of cathepsin B. *Neurochem Res* **37**:31–39.
- Ni J, Wu Z, Peterts C, Yamamoto K, Qing H, and Nakanishi H (2015) The critical role of proteolytic relay through cathepsins B and E in the phenotypic change of microglia/macrophage. *J Neurosci* **35**:12488–12501.
- Ni J, Wu Z, Stoka V, Meng J, Hayashi Y, Peters C, Qing H, Turk V, and Nakanishi H (2019) Increased expression and altered subcellular distribution of cathepsin B in microglia induce cognitive impairment through oxidative stress and inflammatory response in mice. *Aging Cell* **18**:e12856.
- Nilsson E, Bodolea C, Gordh T, and Larsson A (2013) Cerebrospinal fluid cathepsin B and S. *Neurosci Sci* **34**:445–448.
- Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Taylor K, Wiltgen B, Hatami A, Röncke R, et al. (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamyated amyloid- $\beta$ . *Nature* **485**:651–655.
- Offen D, Barhum Y, Melamed E, Embacher N, Schindler C, and Ransmayr G (2009) Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant. *J Mol Neurosci* **38**:85–93.
- Orihuela R, McPherson CA, and Harry GJ (2016) Microglial M1/M2 polarization and metabolic states. *Br J Pharmacol* **173**:649–665.
- Oti M, Falck J, Huynen MA, and Zhou H (2016) CTCF-mediated chromatin loops enclose inducible gene regulatory domains. *BMC Genomics* **17**:252.
- Padamsey Z, McGuinness L, Bardo SJ, Reinhart M, Tong R, Hedegaard A, Hart ML, and Emptage NJ (2017) Activity-dependent exocytosis of lysosomes regulates the structural plasticity of dendritic spines. *Neuron* **93**:132–146.
- Paigen K (2003) One hundred years of mouse genetics: an intellectual history. I. The classical period (1902–1980). *Genetics* **163**:1–7.
- Palmiter RD and Brinster RL (1985) Transgenic mice. *Cell* **41**:343–345.

- Parent AT and Thinakaran G (2010) Modeling presenilin-dependent familial Alzheimer's disease: emphasis on presenilin substrate-mediated signaling and synaptic function. *Int J Alzheimers Dis* **2010**:825918.
- Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, and Myers RM (1998) Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. *Nat Genet* **20**:251–258.
- Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, D'Amato E, Ramirez L, Faham M, Koskineniemi M, et al. (1996) Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). *Science* **271**:1731–1734.
- Pettitt SJ, Liang Q, Rairdan XY, Moran JL, Prosser HM, Beier DR, Lloyd KC, Bradley A, and Skarnes WC (2009) Agouti C57BL/6N embryonic stem cells for mouse genetic resources. *Nat Methods* **6**:493–495.
- Picini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D'Arrigo C, Bachi A et al. (2005) beta-amyloid is different in normal aging and in Alzheimer disease. *J Biol Chem* **280**:34186–34192.
- Poole S, Singhrao SK, Kesavalu L, Curtis MA, and Crean S (2013) Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. *J Alzheimers Dis* **36**:665–677.
- Portelius E, Bogdanovic N, Gustavsson MK, Volkman I, Brinkmalm G, Zetterberg H, Winblad B, and Blennow K (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. *Acta Neuropathol* **120**:185–193.
- Price DL and Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. *Annu Rev Neurosci* **21**:479–505.
- Qian F, Frankfater A, Chan SJ, and Steiner DF (2011) The structure of the mouse cathepsin B gene and its putative promoter. *DNA Cell Biol* **10**:159–168.
- Ramsay M, Ngungcu T, and Grayson W (2019) Keratolytic winter erythema: an update. *Dermatopathology (Basel)* **6**:126–132.
- Rawlings ND, Waller M, Barrett AJ, and Bateman A (2014) MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. *Nucleic Acids Res* **42**:D503–D509.
- Reinheckel T, Deussing J, Roth W, and Peters C (2001) Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. *Biol Chem* **382**:735–741.
- Ren K and Torres R (2009) Role of interleukin-1beta during pain and inflammation. *Brain Res Brain Res Rev* **60**:57–64.
- Rendell MS (2019) The journey from gene knockout to clinical medicine: telotristat and sotagliflozin. *Drug Des Devel Ther* **13**:817–824.
- Repnik U and Turk B (2010) Lysosomal-mitochondrial cross-talk during cell death. *Mitochondrion* **10**:662–669.
- Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, Karp ER, De Sanctis GT, Ploegh HL, and Chapman HA (1998) Cathepsin S activity regulates antigen presentation and immunity. *J Clin Invest* **101**:2351–2363.
- Roberts SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, et al. (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. *Hum Mol Genet* **10**:1317–1324.
- Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, and Mucke L (1995) Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. *J Biol Chem* **270**:28257–28267.
- Rodriguez-Franco EJ, Cantres-Rosario YM, Plaud-Valentin M, Romeu R, Rodriguez Y, Skolasky R, Melendez V, Cadilla CL, and Melendez LM (2012) Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis. *PLoS One* **7**:e36571.
- Rohan de Silva HA, Jen A, Wickenden C, Jen LS, Wilkinson SL, and Patel AJ (1997) Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes. *Brain Res Mol Brain Res* **47**:147–156.
- Rong X, Xiang L, Li Y, Yang H, Chen W, Li L, Liang D, and Zhou X (2020) Chronic periodontitis and Alzheimer disease: a putative link of serum proteins identification by 2D-DIGE proteomics. *Front Aging Neurosci* **12**:248.
- Ruff RL and Secrist D (1984) Inhibitors of prostaglandin synthesis or cathepsin B prevent muscle wasting due to sepsis in the rat. *J Clin Invest* **73**:1483–1486.
- Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, et al. (2002) Pyroglutamate-modified amyloid beta-peptides—AbetaN3(pE)—strongly affect cultured neuron and astrocyte survival. *J Neurochem* **82**:1480–1489.
- Ruza P, Quintieri L, Osler A, Calderan A, Biondi B, Floreani M, Guiotto A, and Borin G (2006) Fluorescent, internally quenched, peptides for exploring the pH-dependent substrate specificity of cathepsin B. *J Pept Sci* **12**:455–461.
- Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, and Manley GT; Workshop Scientific Team and Advisory Panel Members (2008) Classification of traumatic brain injury for targeted therapies. *J Neurotrauma* **25**:719–738.
- Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, and Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. *Neuron* **14**:457–466.
- Saido TC, Yamao-Harigaya W, Iwatsubo T, and Kawashima S (1996) Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. *Neurosci Lett* **215**:173–176.
- Samad TA, Moore KA, Saperstein A, Billet S, Allchorne A, Poole S, Bonventre JV, and Woolf CJ (2001) Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. *Nature* **410**:471–475.
- Sandbrink R, Banati R, Masters CL, Beyreuther K, and König G (1993) Expression of L-APP mRNA in brain cells. *Ann N Y Acad Sci* **695**:183–189.
- Saris CG, Groen EJ, Koekkoek JA, Veldink JH, and van den Berg LH (2013) Meta-analysis of gene expression profiling in amyotrophic lateral sclerosis: a comparison between transgenic mouse models and human patients. *Amyotroph Lateral Scler Frontotemporal Degener* **14**:177–189.
- Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, and Saido TC (2017) APP mouse models for Alzheimer's disease preclinical studies. *EMBO J* **36**:2473–2487.
- Sasahara M, Fries JW, Raines EW, Gown AM, Westrum LE, Froesch MP, Bonthron DT, Ross R, and Collins T (1991) PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. *Cell* **64**:217–227.
- Schechter I and Berger A (1967) On the size of the active site in proteases. I. Papain. *Biochem Biophys Res Commun* **27**:157–162.
- Schiller S, Seebode C, Hennies HC, Giehl K, and Emmert S (2014) Palmoplantar keratoderma (PPK): acquired and genetic causes of a not so rare disease. *J Dtsch Dermatol Ges* **12**:781–788.
- Schilling S, Hoffmann T, Manhart S, Hoffmann M, and Demuth HU (2004) Glutamyl cyclases unfold glutamyl cyclase activity under mild acid conditions. *FEBS Lett* **563**:191–196.
- Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Böhm G, and Demuth HU (2006) On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). *Biochemistry* **45**:12393–12399.
- Schlenzig D, Cynis H, Hartlage-Rübsamen M, Zeitschel U, Menge K, Fothe A, Ramsbeck D, Spahn C, Wermann M, Roßner S, et al. (2018) Dipeptidyl-peptidase activity of meprin  $\beta$  links N-truncation of A $\beta$  with glutamyl cyclase-catalyzed pGlu-A $\beta$  formation. *J Alzheimers Dis* **66**:359–375.
- Sevénich L, Pennacchio LA, Peters C, and Reinheckel T (2006) Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice. *Biol Chem* **387**:885–891.
- Sevénich L, Schurigt U, Sachse K, Gajda M, Werner F, Müller S, Vasiljeva O, Schwinde A, Klemm N, Deussing J, et al. (2010) Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. *Proc Natl Acad Sci USA* **107**:2497–2502.
- Seyfried D, Han Y, Zheng Z, Day N, Moïn K, Rempel S, Sloane B, and Chopp M (1997) Cathepsin B and middle cerebral artery occlusion in the rat. *J Neurosurg* **87**:716–723.
- Seyfried DM, Veyna R, Han Y, Li K, Tang N, Betts RL, Weinsheimer S, Chopp M, and Anagli J (2001) A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia. *Brain Res* **901**:94–101.
- Sharma A, Swetha B, Bajad NG, Ganeshpurkar A, Singh R, Kumar A, and Singh SK (2022) Cathepsin B—a neuronal death mediator in Alzheimer's disease leads to neurodegeneration. *Mini Rev Med Chem* **10.2174/13895575226662202114095859** [published ahead of print].
- Singhrao SK, Harding A, Poole S, Kesavalu L, and Crean S (2015) Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer's disease. *Mediators Inflamm* **2015**:137357.
- Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL, and Rao JS (1995) Overexpression and localization of cathepsin B during the progression of human gliomas. *Clin Exp Metastasis* **13**:49–56.
- Sochocka M, Zwolińska K, and Leszek J (2017) The infectious etiology of Alzheimer's disease. *Curr Neuropharmacol* **15**:996–1009.
- Stanford WL, Cohn JB, and Cordes SP (2001) Gene-trap mutagenesis: past, present and beyond. *Nat Rev Genet* **2**:756–768.
- Stoka V, Turk V, and Turk B (2016) Lysosomal cathepsins and their regulation in aging and neurodegeneration. *Ageing Res Rev* **32**:22–37.
- Sun L, Wu Z, Hayashi Y, Peters C, Tsuda M, Inoue K, and Nakanishi H (2012) Microglial cathepsin B contributes to the initiation of peripheral inflammation-induced chronic pain. *J Neurosci* **32**:11330–11342.
- Sun Y, Rong X, Lu W, Peng Y, Li J, Xu S, Wang L, and Wang X (2015) Translational study of Alzheimer's disease (AD) biomarkers from brain tissues in A $\beta$ /PP/PS1 mice and serum of AD patients. *J Alzheimers Dis* **45**:269–282.
- Sun YX, Dai DK, Liu R, Wang T, Luo CL, Bao HJ, Yang R, Feng XY, Qin ZH, Chen XP, et al. (2013) Therapeutic effect of SN50, an inhibitor of nuclear factor- $\kappa$ B, in treatment of TBI in mice. *Neurol Sci* **34**:345–355.
- Sundelöf J, Sundström J, Hansson O, Eriksson-Jönheden M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, et al. (2010) Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. *J Alzheimers Dis* **22**:1223–1230.
- Sweitzer S, Martin D, and DeLeo JA (2001) Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. *Neuroscience* **103**:529–539.
- Takahashi T, Dehdarani AH, Yonezawa S, and Tang J (1986) Porcine spleen cathepsin B is an exopeptidase. *J Biol Chem* **261**:9375–9381.
- Takio K, Towatari T, Katunuma N, Teller DC, and Titani K (1983) Homology of amino acid sequences of rat liver cathepsins B and H with that of papain. *Proc Natl Acad Sci USA* **80**:3666–3670.
- Tamai M, Matsumoto K, Omura S, Koyama I, Ozawa Y, and Hanada K (1986) *In vitro* and *in vivo* inhibition of cysteine proteinases by EST, a new analog of E-64. *J Pharmacobiodyn* **9**:672–677.
- Tanaka S, Shiojiri S, Takahashi Y, Kitaguchi N, Ito H, Kameyama M, Kimura J, Nakamura S, and Ueda K (1989) Tissue-specific expression of three types of beta-protein precursor mRNA: enhancement of protease inhibitor-harboring types in Alzheimer's disease brain. *Biochem Biophys Res Commun* **165**:1406–1414.
- Tang T, Li L, Tang J, Li Y, Lin WY, Martin F, Grant D, Solloway M, Parker L, Ye W, et al. (2010) A mouse knockout library for secreted and transmembrane proteins. *Nat Biotechnol* **28**:749–755.
- Tanghe A, Termont A, Merchiers P, Schilling S, Demuth HU, Scrocchi L, Van Leuven F, Griffioen G, and Van Dooren T (2010) Pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer's disease of the APP[V717I] London transgenic mouse model. *Int J Alzheimers Dis* **2010**:417314.
- Tedelind S, Poliakov K, Valeta A, Hunegnaw R, Yemanaberhan EL, Helden NE, Kurebayashi J, Weber E, Kopitar-Jerala N, Turk B, et al. (2010) Nuclear cysteine cathepsin variants in thyroid carcinoma cells. *Biol Chem* **391**:923–935.

- Teixeira FB, Saito MT, Matheus FC, Prediger RD, Yamada ES, Maia CSF, and Lima RR (2017) Periodontitis and Alzheimer's disease: a possible comorbidity between oral chronic inflammatory condition and neuroinflammation. *Front Aging Neurosci* **9**:327.
- Terada K, Yamada J, Hayashi Y, Wu Z, Uchiyama Y, Peters C, and Nakanishi H (2010) Involvement of cathepsin B in the processing and secretion of interleukin-1beta in chromogranin A-stimulated microglia. *Glia* **58**:114–124.
- Tholen S, Biniössek ML, Gansz M, Gomez-Auli A, Bengsch F, Noel A, Kizhakkedathu JN, Boerries M, Busch H, Reinheckel T, et al. (2013) Deletion of cysteine cathepsins B or L yields differential impacts on murine skin proteome and degradation. *Mol Cell Proteomics* **12**:611–625.
- Tribuzi R, Crispoltoni L, Porcellati S, Di Lullo M, Florenzano F, Pirro M, Bagaglia F, Kawarai T, Zampolini M, Orlacchio A, et al. (2014) miR128 up-regulation correlates with impaired amyloid  $\beta$ (1-42) degradation in monocytes from patients with sporadic Alzheimer's disease. *Neurobiol Aging* **35**:345–356.
- Towatari T, Nikawa T, Murata M, Yokoo C, Tamai M, Hanada K, and Katunuma N (2011) Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. *FEBS Lett* **280**:311–315.
- Tschopp J and Schroder K (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? *Nat Rev Immunol* **10**:210–215.
- Tsubokawa T, Yamaguchi-Okada M, Calvert JW, Solaroglu I, Shimamura N, Yata K, and Zhang JH (2006) Neurovascular and neuronal protection by E64d after focal cerebral ischemia in rats. *J Neurosci Res* **84**:832–840.
- Tsuchiya K, Hosojima S, Hara H, Kushiyama H, Mahib MR, Kinoshita T, and Suda T (2021) Gasdermin D mediates the maturation and release of IL-1 $\alpha$  downstream of inflammasomes. *Cell Rep* **34**:108887.
- Tsuchiya K, Kohda Y, Yoshida M, Zhao L, Ueno T, Yamashita J, Yoshioka T, Kominami E, and Yamashima T (1999) Postictal blockade of ischemic hippocampal neuronal death in primates using selective cathepsin inhibitors. *Exp Neurol* **155**:187–194.
- Tu C, Ortega-Cava CF, Chen G, Fernandes ND, Cavallo-Medved D, Sloane BF, Band V, and Band H (2008) Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. *Cancer Res* **68**:9147–9156.
- Turk B, Turk D, and Salvesen GS (2002) Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. *Curr Pharm Des* **8**:1623–1637.
- Turk V and Bode W (1991) The cystatins: protein inhibitors of cysteine proteinases. *FEBS Lett* **285**:213–219.
- Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, and Turk D (2012) Cysteine cathepsins: from structure, function and regulation to new frontiers. *Biochim Biophys Acta* **1824**:68–88.
- Uccellini MB, Bardina SV, Sánchez-Aparicio MT, White KM, Hou YJ, Lim JK, and García-Sastre A (2020) Passenger mutations confound phenotypes of SARM1-deficient mice. *Cell Rep* **31**:107498.
- Uchiyama Y, Shibata M, Koike M, Yoshimura K, and Sasaki M (2008) Autophagy-physiology and pathophysiology. *Histochem Cell Biol* **129**:407–420.
- Van Cauwenbergh C, Van Broeckhoven C, and Sleegers K (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. *Genet Med* **18**:421–430.
- Vanden Berghe T, Goethals A, Demon D, Bogaert P, Mak TW, Cauwels A, and Vandenabeele P (2013) An inactivating caspase-11 passenger mutation muddles sepsis research. *Am J Respir Crit Care Med* **188**:120–121.
- Vanden Berghe T, Hulpiau P, Martens L, Vandenbroucke RE, Van Wouterghem E, Perry SW, Bruggeman I, Divert T, Choi SM, Vuyksteke M, et al. (2015) Passenger mutations confound interpretation of all genetically modified congenic mice. *Immunity* **43**:200–209.
- Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Krüger A, Schurig U, Sevenich L, Turk B, Peters C, et al. (2008) Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. *Oncogene* **27**:4191–4199.
- Vassar R (2004) BACE1: the beta-secretase enzyme in Alzheimer's disease. *J Mol Neurosci* **23**:105–114.
- Verderio C, Cagnoli C, Bergami M, Francolini M, Schenk U, Colombo A, Riganti L, Frasson C, Zuccaro E, Danglot L, et al. (2012) TI-VAMP/VAMP7 is the SNARE of secretory lysosomes contributing to ATP secretion from astrocytes. *Biol Cell* **104**:213–228.
- Verkhatsky A, Matteoli M, Parpura V, Mothet JP, and Zorec R (2016) Astrocytes as secretory cells of the central nervous system: idiosyncrasies of vesicular secretion. *EMBO J* **35**:239–257.
- Viana GM, Gonzalez EA, Alvarez MMP, Cavalheiro RP, do Nascimento CC, Baldo G, D'Almeida V, de Lima MA, Pshezhetsky AV, and Nader HB (2020) Cathepsin B-associated activation of amyloidogenic pathway in murine mucopolysaccharidosis type I brain cortex. *Int J Mol Sci* **21**:1459.
- Vreemann A, Qu H, Mayer K, Andersen LB, Stefana MI, Wehner S, Lysson M, Farcas AM, Peters C, Reinheckel T, et al. (2009) Cathepsin B release from rodent intestine mucosa due to mechanical injury results in extracellular matrix damage in early post-traumatic phases. *Biol Chem* **390**:481–492.
- Wang C, Sun B, Zhou Y, Grubb A, and Gan L (2012) Cathepsin B degrades amyloid- $\beta$  in mice expressing wild-type human amyloid precursor protein. *J Biol Chem* **287**:39834–39841.
- Wang L, Chen Y, Li X, Zhang Y, Gulbins E, and Zhang Y (2016) Enhancement of endothelial permeability by free fatty acid through lysosomal cathepsin B-mediated Nlrp3 inflammasome activation. *Oncotarget* **7**:73229–73241.
- Wang PH, Do YS, Macaulay L, Shinagawa T, Anderson PW, Baxter JD, and Hsueh WA (1991) Identification of renal cathepsin B as a human prorenin-processing enzyme. *J Biol Chem* **266**:12633–12638.
- Wang Y, Gao A, Xu X, Dang B, You W, Li H, Yu Z, and Chen G (2015) The neuroprotection of lysosomotropic agents in experimental subarachnoid hemorrhage probably involving the apoptosis pathway triggering by cathepsins via chelating intralysosomal iron. *Mol Neurobiol* **52**:64–77.
- Wang Y, Gu ZL, Cao Y, Liang ZQ, Han R, Bennett MC, and Qin ZH (2006) Lysosomal enzyme cathepsin B is involved in kainic acid-induced excitotoxicity in rat striatum. *Brain Res* **1071**:245–249.
- Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P, et al.; Mouse Genome Sequencing Consortium (2002) Initial sequencing and comparative analysis of the mouse genome. *Nature* **420**:520–562.
- Weiler R, Lassmann H, Fischer P, Jellinger KA, and Winkler H (1990) A high ratio of chromogranin A to synaptin/synaptophysin is a common feature of brains in Alzheimer and Pick disease. *FEBS Lett* **263**:337–339.
- Weiss FU, Behn CO, Simon P, Ruthenbürger M, Halangk W, and Lerch MM (2007) Cathepsin B gene polymorphism Val26 is not associated with idiopathic chronic pancreatitis in European patients. *Gut* **56**:1322–1323.
- Willem M, Lammich S, and Haass C (2009) Function, regulation and therapeutic properties of beta-secretase (BACE1). *Semin Cell Dev Biol* **20**:175–182.
- Wilson SR, Peters C, Saftig P, and Brömme D (2009) Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. *J Biol Chem* **284**:2584–2592.
- Wong WPS, Altamus JB, Hester JF, Chan ER, Côté JF, Serre D, and Sehayek E (2013) Cathepsin B is a novel gender-dependent determinant of cholesterol absorption from the intestine. *J Lipid Res* **54**:816–822.
- Wu Z, Liu X, Cheng L, and Ye K (2020) Delta-secretase triggers Alzheimer's disease pathologies in wild-type hAPP/hMAPT double transgenic mice. *Cell Death Dis* **11**:1058.
- Wu Z, Ni J, Liu Y, Teeling JL, Takayama F, Colcutt A, Ibbett P, and Nakanishi H (2017) Cathepsin B plays a critical role in inducing Alzheimer's disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from *Porphyromonas gingivalis* in mice. *Brain Behav Immun* **65**:350–361.
- Xie Z and Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. *Nat Cell Biol* **9**:1102–1109.
- Yamashima T, Kohda Y, Tsuchiya K, Ueno T, Yamashita J, Yoshioka T, and Kominami E (1998) Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis'. *Eur J Neurosci* **10**:1723–1733.
- Yan X, Wu Z, Wang B, Yu T, Hu Y, Wang S, Deng C, Zhao B, Nakanishi H, and Zhang X (2020) Involvement of cathepsins in innate and adaptive immune responses in periodontitis. *Evid Based Complement Alternat Med* **2020**:4517587.
- Yasuhara O, Kawamata T, Aimi Y, McGeer EG, and McGeer PL (1994) Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases. *Neurosci Lett* **170**:13–16.
- Yoon MC, Solania A, Jiang Z, Christy MP, Podvin S, Mosier C, Lietz CB, Ito G, Gerwick WH, Wolan DW, et al. (2021) Selective neutral pH inhibitor of cathepsin B designed based on cleavage preferences at cytosolic and lysosomal pH conditions. *ACS Chem Biol* **16**:1628–1643.
- Yoshida M, Yamashima T, Zhao L, Tsuchiya K, Kohda Y, Tonchev AB, Matsuda M, and Kominami E (2002) Primate neurons show different vulnerability to transient ischemia and response to cathepsin inhibition. *Acta Neuropathol* **104**:267–272.
- Yu ZQ, Jia Y, and Chen G (2014) Possible involvement of cathepsin B/D and caspase-3 in deafferentation-related neuroprotection of early brain injury after subarachnoid haemorrhage in rats. *Neuropathol Appl Neurobiol* **40**:270–283.
- Zambrowicz BP and Sands AT (2003) Knockouts model the 100 best-selling drugs—will they model the next 100? *Nat Rev Drug Discov* **2**:38–51.
- Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, et al. (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease [published correction appears in *J Alzheimers Dis* **9**:81–88]. *J Alzheimers Dis* **7**:125–133; discussion 173–180.
- Zhang YB, Chen XP, Tao LY, Qin ZH, Li SX, Yang L, Yang J, Zhang YG, and Liu R (2006) [Expression of cathepsin-B and -D in rat's brain after traumatic brain injury]. *Fa Yi Xue Za Zhi* **22**:404–406, 410.
- Zhang Z, Song M, Liu X, Su Kang S, Duong DM, Seyfried NT, Cao X, Cheng L, Sun YE, Ping Yu S, et al. (2015) Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease. *Nat Commun* **6**:8762.
- Zhao H, Alam A, Chen Q, A Eusman M, Pal A, Eguchi S, Wu L, and Ma D (2017) The role of microglia in the pathobiology of neuropathic pain development: what do we know? *Br J Anaesth* **118**:504–516.
- Zhao L, Zhu Y, Wang D, Chen M, Gao P, Xiao W, Rao G, Wang X, Jin H, Xu L, et al. (2010) Morphine induces Beclin 1- and ATG5-dependent autophagy in human neuroblastoma SH-SY5Y cells and in the rat hippocampus. *Autophagy* **6**:386–394.
- Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, and Jaenisch R (1990) Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. *Nature* **344**:742–746.